Curriculum Vitae
LINDA P. DWOSKIN, Ph.D.
Professor of Pharmaceutical Sciences
Endowed Professor of Pharmaceutical Education
Director of the National Cooperative Drug Discovery Group
University of Kentucky, College of Pharmacy
Department of Pharmaceutical Sciences
Department of Behavioral Sciences*
Rose Street, Lexington, KY 40536-0082
Tel. (859) 257-4743 Fax (859) 323-3575
email: ldwoskin@email.uky.edu
Center on Drug Abuse Translation
Graduate Center for Toxicology Associate Faculty
Multi-disciplinary Center on Drug and Alcohol Abuse
Center for Membrane Sciences
University of Kentucky
*Joint appointment
I.
II.
III.
General Information
Home Address:
2249 Abbeywood Rd.
Lexington, KY 40515
Office Address:
411B College of Pharmacy
725 Rose Street
University of Kentucky
Lexington, KY 40536-0082
Children:
Miranda (Mandy) Felice Stein
Haley Paula Stein
Education
1971-1974
1974-1976
B.S.
Graduate Ed.
1976-1983
Ph.D.
Professional Experience
1983-1984
Postdoctoral Fellow
1984-1986
Postdoctoral Fellow
Telephone:
(859) 272-7814
Telephone:
Lab:
FAX:
(859) 257-4743
(859) 257-2555
(859) 323-3575
Born: August 17, 1989
Born: December 31, 1993
Syracuse University, Syracuse, NY
Syracuse University, Syracuse, NY
Advisor: Dr. Matthew Wayner
University of Minnesota, Minneapolis, MN
Advisor: Dr. Sheldon B. Sparber
Univ of Oregon Health Sciences Center
Dept. of Endocrinology; Portland, Oregon
Mentor: Dr. John Kendall
Univ of Colorado Health Sciences Center
Dept. of Pharmacology; Denver, Colorado
Mentor: Dr. Nancy R. Zahniser
Linda P. Dwoskin
Curriculum Vitae
Page 2
IV.
V.
Academic Appointments
1986-1988
Instructor
Full-time
Univ of Colorado Health Sciences Center
Dept of Pharmacology, Denver, Colorado
Dr. Norman Weiner, Department Chairman
Dr. Robert Murphy, Acting Dept. Chairman
1988-1994
Assist. Professor
Pharmaceutical Sciences Division
College of Pharmacy University of Kentucky
Dr. Mark Gillespie, Director
Dr. Jordan Cohen, Dean
Lexington, Kentucky
1994-1999
Assoc. Professor
Pharmaceutical Sciences Division
College of Pharmacy University of Kentucky
Dr. Patrick DeLuca, Chairman
Dr. Jordan Cohen, Dean
1999-
Professor
Department of Pharmaceutical Sciences
College of Pharmacy University of Kentucky
Dr. Pat McNamara, Chairman
Dr. Kenneth Roberts, Dean
1990-
Adjunct Faculty
University of Kentucky Graduate Center
for Toxicology, Lexington, Kentucky
Dr. Mary Vore, Director
1990-
Associate
University of Kentucky Center on Drug
Abuse Translation, Lexington, Kentucky
Dr. Michael T. Bardo, Director
1993-
Associate
Multi-disciplinary Research Center on Drug
and Alcohol Abuse, Lexington, Kentucky
Dr. Carl G. Leukefeld, Director
1999-
Associate
Center for Membrane Sciences
Lexington, Kentucky
Dr. Allan Butterfield, Director
2003-
Professor
Department of Behavioral Sciences
Dr. Carl G. Leukefeld, Chairman
Hospital or Clinical Appointments
Not applicable.
Linda P. Dwoskin
Curriculum Vitae
Page 3
VI.
Instructional Activity - Regular Courses
A. Course Coordinator Responsibility:
University of Kentucky:
PHR 760 Topics in Pharmaceutics: Neuropharmacology, Course Coordinator
1991-1998, 10 graduate students
PHR 760-008: Molecular Neurobiology of Abused Drugs, Course Coordinator (3 credits)
2005, 15 graduate students, 4 lectures
PHR 851 Pharmacotherapeutics: Nervous System, Course Coordinator
1988-1992, 100 undergraduate students, 35 lectures
PHR 336 Physiologic Basis for Therapeutics I, Course Coordinator
1993-1994, 115 professional pharmacy students, 25 lectures
PHR 911 Physiologic Basis of Therapeutics I, Course Coordinator
1995-1998, 80 professional pharmacy students, 30 lectures
B. Course Contribution:
Syracuse University
PSY 590 Physiological Psychology and Laboratory
1974-76, 40 undergraduate students, 10 tutorial sessions
University of Colorado Health Sciences Center
PHCL 620 Introduction to Pharmacology
1986-87, 8 graduate students, 6 lectures
DHDD 402 Pharmacology for Dental Hygienists
1986-87, 30 undergraduate students, 2 lectures
University of Kentucky:
PHR 911 Physiologic Basis of Therapeutics I
1999-2001, ~100 professional pharmacy students, 9 lectures
PHR 931 Pharmacotherapeutics: Nervous System
1996-1998, 2003-present, 5-10 lectures, 130 pharmacy students
PHR 851 Pharmacotherapeutics: Nervous System, 1988-1992, 35 lectures
1993-1995, 8 lectures, 100 professional pharmacy students
PHR 336 Physiologic Basis for Therapeutics I
1988-1990, 3 lectures; 1995-1998, 25 lectures, 90 professional
pharmacy students
PHR 649 Molecular Pharmacology
1993-1996, 10 graduate students, 4 lectures
PHR 760 Molecular Neurobiology of Abused Drugs
Course Coordinator, 2005-present, 15 graduate students and
postdocs, 4 lectures
PHR760 Topics in Pharmaceutical Sciences: Drug Targets and Actions, 2006,
15 graduate students and postdocs, 3 lectures
PHR760 Advanced Neuropharmacology,
2001, 3 graduate students, 2 lectures
PHR 760 Introduction to Pharmaceutical Sciences
Linda P. Dwoskin
Curriculum Vitae
Page 4
PHR 778
TOX 770
TOX 780
TOX 600
NEU 605
PHA 602
PSY 776
CDA
DSP130
1999-2001, 12 graduate students, 1 lecture
Pharmaceutical Sciences Seminar; Seminar Advisor
1992-present, mentor 1-2 graduate students
Toxicology Journal Club
2001, 10 graduate students, 1 lecture
Special Problems in Toxicology: Neurotoxicology
1991-2000, 10 graduate students, 4 lectures
Ethics, 2003, 12 graduate students, 1 lecture
Contemporary Neurosciences
1989-1995, 20 graduate students, 2 lectures
Advanced Neuropharmacology
1991-1995, 10 graduate students, 2 lectures
Dependency Behavior
1995-2000, 10 graduate students, 1 lecture
Female Drug Abuse Science Curriculum
1999-2001, 2004-present Center on Drug Abuse Summer Course
2 lectures, 25 high school students
The Biology of Alcohol and Other Psychoactive Drugs (3 credits)
2005, 15 undergraduate students, 1 lecture
VII. Advising Activity
A. Graduate Students
University of Colorado
11/86-02/87
Cynthia Wilcox
Dept of Pharmacology
University of Kentucky (Chair of Dissertation Committee)
05/90-4/94
Ann Jewell
College of Pharmacy
09/92-05/97
LiHong Teng
Graduate Ctr Toxicology
09/97-01/98
Matt Grapentine
College of Pharmacy
07/94-08/01
Lincoln Wilkins
College of Pharmacy
08/99-10/05
Lisa Middleton
College of Pharmacy
03/03-09/03
Miranda Crowe
College of Pharmacy
03/03-11/03
Diana Ramsey
College of Pharmacy
02/06-08/07
Kelly A. King-Pospisil
Graduate Ctr Toxicology
08/03Yolanda Williams
College of Pharmacy
08/04David Horton
College of Pharmacy
09/05Vidya Narayanaswami
College of Pharmacy
01/08Zhang Cao
College of Pharmacy
B. Graduate Student Dissertation Committees at University of Kentucky:
1990-1992
Cynthia Crawford (Member)
Department of Psychology
1990-1993
Dave Allen (Member)
College of Pharmacy
1991-1993
James Rowlett (Member)
Department of Psychology
1992-1993
YingShi Guo (Member)
Graduate Ctr Toxicology
1990-1994
Ann Jewell (Chairman)
College of Pharmacy
Linda P. Dwoskin
Curriculum Vitae
Page 5
1991-1994
Bryan Tolliver (Member)
Dept of Pharmacology
1991-1995
Michelle Niehi (Member)
Graduate Ctr Toxicology
1992-1995
Danny Kao (Member)
College of Pharmacy
1993*
Minghua Shan (Outside)
Biostatistics Department
1995*
Ye-Ming Sun (Outside)
Biological Sciences
1990-1996
Jerry Meyer (Member)
College of Pharmacy
1994-1996
Min Li (Member)
College of Pharmacy
1995-1996
Joanne Valone (Member)
Department of Psychology
1996*
Somasun Gabbita (Outside)
Graduate Ctr Toxicology
1992-1997
LiHong Teng (Chairman)
Graduate Ctr Toxicology
1993-1997
David Ackley (Member)
College of Pharmacy
1997-1998
Matt Grapentine (Chairman)
College of Pharmacy
1995-1998
Chinh Vu (Member)
College of Pharmacy
1995-1998
Patricia Robinet (Member)
Department of Psychology
1997-1998
Wendell Scott Akers (Member) College of Pharmacy
1996-1998
Jason Swango (Member)
College of Pharmacy
1998*
Lynne Trench (Member)
Department of Psychology
1997-1999
Jae Sparks (Member)
College of Pharmacy
1995-1999
Victoria King (Member)
College of Pharmacy
1997-2000
Omar Ghosheh (Member)
College of Pharmacy
2000*
Tracy Segar (member)
Department of Psychology
1998-2001
Kevin Sheehan (Member)
College of Pharmacy
1995-2001
Lincoln Wilkins (Chairman)
College of Pharmacy
1998-2001
Marlon Jones (Member)
Chemistry Department
1999-2002
Leigh Verbois (Member)
College of Pharmacy
1998-2002
Tom Green (Member)
Department of Psychology
2002*
Angie Makris (Outside)
Behavioral Sciences 20012003
Hongna Wang (Member)
College of Pharmacy
1998-2004
Gerome Burke (Member)
Graduate Ctr Toxicology
2002-2005
Brian Keith Day (Member)
Anatomy & Neurobiology
1999-2005
Lisa Middleton (Chairman)
College of Pharmacy
1998-2006
Josh Ayers (Member)
College of Pharmacy
2001Aaron Haubner (Member)
College of Pharmacy
2002Nichole Neugebauer (Member) Department of Psychology
2002-2006
Jeremiah Gates (Member)
Anatomy & Neurobiology
2003Yolanda Williams (Chair)
College of Pharmacy
2004David Horton (Chair)
College of Pharmacy
2005Tom Wooters (Member)
Department of Psychology
2005Tom Woodcock (Member)
College of Pharmacy
2005Vidya Narayanaswami (Chair)
College of Pharmacy
2006Kelly A. King-Pospisil (Chair)
Graduate Ctr Toxicology
2006John Culver (Member)
College of Pharmacy
2007Stephanie Morris (Member)
College of Pharmacy
2008Zhang Cao (Chair)
College of Pharmacy
Note: Asterisk (*) indicates Outside Reviewer for Dissertation Committee
Linda P. Dwoskin
Curriculum Vitae
Page 6
C. Graduate student rotating in the Dwoskin lab
2005
Stephanie Morris
2005
John Culver
2005
Mike Smith
2005
Vidya Narayanaswami
2006
Kelly A. King-Pospisil
2006
Jingjing Liu
2006
Kamalika Mukherjee
2006
Donna J. Coy
2007
Cao Zheng
Pharmaceutical Sciences
Pharmaceutical Sciences
Pharmaceutical Sciences
Pharmaceutical Sciences
Graduate Ctr Toxicology
Pharmaceutical Sciences
Pharmaceutical Sciences
Graduate Ctr Toxicology
Pharmaceutical Sciences
D. Postdoctoral Fellows and Research Associates
Current Position
09/93-08/94 Patricia Manderscheid, PhD USA
08/96-04/97 Ed Barnes, PhD
USA
03/99-06/02 Vladimir Grinevich, MD, PhD Belarus Targacept Inc, scientist
08/99-08/02 Dennis Miller, PhD
USA
Univ Missouri, faculty
08/00-12/03 Steven Harrod, PhD
USA
Univ So Carolina, faculty
07/01-07/03 Seth Norrholm, PhD
USA
Emory Univ, faculty
09/02-01/05 Sairam Krishnamurthy, PhD India
Banaras Hindu Univ, faculty
04/00-01/06 Jun Zhu, MD, PhD
China Univ South Carolina faculty
11/03-10/05 Gurpreet Dhawan, PhD
India
Univ Heidelberg, post doc
04/01-10/06 Sangeetha Sumithran, PhD India
11/06-12/07 Barry Matt Joyce, PhD
USA
Eli Lilly, scientist
10/05Margarita Pivovarchik, PhD Belarus
07/06Justin Nickell, PhD
USA
08/06Siripurapu Kiran Babu, PhD India
12/06Jaturaporn Chagkutip, PhD Thailand
04/07Andrew Smith, PhD
USA
01/08Yuri Klyachkin, PhD
USA
E. Professional Pharmacy Students (ASK Program)
2003
Melissa Catron
2001
Daniel Elmore
2001
Joy Gerk
2004
Dana Hayes
2004
Sean Heineman
2006
Rebecca Heath
F. Summer Students
2001
Alison Anderson, B.S.
2001
Anne Marie Woods
2001
Jacqueline Perez
2001
Bobbi Mullins
2001
Christina Davis
2001
Nichole M. Neugebauer
2002
Carmen Ruiz
Berea College (lab rotation)
Pharmaceutical Sci Summer Program
Graduate Center for Toxicology
Young Women in Science
Young Women in Science
University of Massachusetts
Graduate Center for Toxicology
Linda P. Dwoskin
Curriculum Vitae
Page 7
2002
2002
2004
2005
2005
2006
2006
2007
2007
2007
Maegan Risner
Hannah Tackett
Ron Bruntz
Anna Maria Noriega
Jennifer Furman
Rachel Vickers
Omayra Gonzalez
Sheritta White
Christina Nelson
Jenny Rios
Young Women in Science
Young Women in Science
Pharmaceutical Sci Summer Program
Graduate Center for Toxicology
Pharmaceutical Sci Summer Program
Asbury College
Graduate Center for Toxicology
Bucks for Brains
Pharmaceutical Sci Summer Program
Graduate Center for Toxicology
G. Exchange Students
2001-2002 David Eaves
2003-2004 Sarah White
2004-2005 Nicola Butcher
2005-2006 Emily Kennard
2006-2007 Hayley Notton
University of Bath, England
University of Bath, England
University of Bath, England
University of Bath, England
University of Bath, England
H. Independent Study Students
2002-2003 Jennifer Douglas
2003-2004 Bobbi Mullins
2004-2005 Ron Bruntz
2004-2006 Lana Ng
2006-2007 Aimee Passafiume
2006-2007 Emily Ann Boots
Biology
Biology
Biology
Chemistry
Chemistry
Pre-Pharmacy
I. High School Students
2003-2004 Chris Jones
2004-2005 Tracy Watts
Lafayette High School
Dunbar High School
J. Faculty Mentoring
2003-2005 Anita Fernander
2004-2005 Greg Graff
2005Kim Nixon
2006-2007 Jun Zhu
Behavioral Sciences
College of Pharmacy
College of Pharmacy
College of Pharmacy
VIII. Administrative Activity and University Service
A. College of Pharmacy Committees
1988-1989 Admissions Committee
1988-1989 Space Committee
1989-1991 Research and Seminar Committee
1989
Director Search Committee for Biomedical Mass Spectroscopist
1990-1993 Health and Drug Education Committee
1991-1997 Academic Performance Committee
1994-1996 Research and Seminar Committee
Linda P. Dwoskin
Curriculum Vitae
Page 8
1995
1996-1997
1998
1998
1998
1998
1998-1999
1999
1999-2000
2001-2002
2001-2002
2002-2003
2002-2003
2002
2003-2005
2004-2005
2004-2005
2004-2006
Faculty Search Committee for PET Division
Accreditation Committee, Faculty Subcommittee
Pharmaceutical Sciences Executive Committee
Research Initiative, Equipment Requests
Faculty Search Committee for Pharmacy Practice & Science
Pharmaceutical Sciences Interim Chairman Search Committee
Pharmaceutical Sciences Chairman Search Committee
Chairman-Research and Seminar Committee
Promotion and Tenure Committee
Facilities Expansion Committee
Promotion and Tenure Committee
ACPE Self-Study, Financial Subcommittee
Chairman, Promotion and Tenure Committee
Co-Chair Pharmaceutical Sciences Chair Search Committee
Promotion and Tenure Committee
Neuroscience Faculty Search Committee, Pharmaceutical Sciences
Seminar Advisory Committee
Pharmaceutical Sciences Executive Committee, Elected member
B. University Committees
1989-1993 Academic Council for the Medical Center
1991-1994 Chairman - Minority Affairs Committee - Grad. Ctr. Toxicol.
1995-1998 Chemical Safety Committee
1995-1998 Institutional Animal Care and Use Committee (IACUC)
Medical Center Subcommittee
1996-1998 University Senate Standing Committee
Ad Hoc Committee on Status of Women
1996-1998 Medical Center Committee on International Affairs
1996-1998 Executive Committee for University of Kentucky
Integrative Neuroscience Program
1998-1999 Faculty Search Committee, Graduate Ctr Tox Res Challenge Line
2001-2005 Academic Council for the Medical Center
2004-2005 Graduate Council
2002-2005 Task Force on Drug Development/Natural Products
2004-2005 Academic Council of the Medical Center
2004-2005 University of Kentucky Graduate Council
2005-2008 University of Kentucky Senate
2005-2007 University of Kentucky Senate –Research Committee
2006-2007 University Committee on Strategic Planning and Priorities, Faculty
Development Subcommittee
2006-2008 Academic Area Advisory Committee for the Biological Sciences
2008
UK External Review Committee, Dept Behavioral Sciences
IX.
Special Assignments
1988-1998 Controlled Substances Officer, College of Pharmacy
Linda P. Dwoskin
Curriculum Vitae
Page 9
X.
Honors
1980-1982
1983-1984
1983-1984
1985-1986
1988
1988
1997
2000
2002-2007
2002-2007
2003
2005-2006
2007
2007
2007
XI.
U.S. Public Health Service, Predoctoral Fellowship
U.S. Public Health Service, Postdoctoral Fellowship
Tartar Trust Research Fellowship, Oregon Health Science Center
National Institutes of Health, Postdoctoral Fellowship
Winter Conference on Brain Research, Fellowship Award
Rho Chi Pharmacy Honor Society - Academic Achievement
Univ Minnesota, NIDA Training Grant Distinguished Alumnus
Faculty Achievement Award, College of Pharmacy, UK
US Surgical-Pfizer Endowed Professorship, UK
Wethington Award for Meritorious Performance in Research
Inducted into the Honorable Order of Kentucky Colonels
University Research Professorship
Endowed Professor of Pharmaceutical Education
Mentor Recognition Award, Clinical and Translational Science
Conference
Circle of Power, Leadership Program for Women Faculty
Professional Activity and Service
A. Professional Organizations
Member - Society for Neuroscience
Member - Behavioral Pharmacology Society
Member - Am Soc for Pharmacology & Experimental Therapeutics (ASPET)
Secretary - ASPET Neuropharmacology Subdivision (1992-2002)
Member - ASPET Women in Pharmacology Committee (1997-2003)
Chairman - ASPET Women in Pharmacology Committee (1999-2002)
Member - International Society for Neurochemistry
Member - Society for Neuroscience Local Chapter
Secretary (1991-1992)
President Elect (2002-2003)
President (2003-2004)
Member - College of the Problems of Drug Dependence (CPDD)
Member - Publications Committee CPDD (1999-2002)
Member - Women in Neuroscience
Vice Chairman - Med Chemistry and Natural Products, Southeastern Regional
Division of the Am Association of Pharmaceutical Sciences (1998-1999)
B. Entrepreneurial Activity
Founder and Vice President - Yaupon Therapeutics (2002- present)
C. Journal Referee
1988-present
1988-present
1990-present
Life Sciences
Journal of Pharmacology & Experimental Therapeutics
Brain Research
Linda P. Dwoskin
Curriculum Vitae
Page 10
1990-present
1993-present
1995-present
1998-present
1999-present
2001-present
2001-present
2003-present
2003-present
2005-present
2005-present
2005-present
Journal of Neurochemistry
Neurotoxicology and Teratology
Neuroscience
Psychopharmacology
Biochemical Pharmacology
Alcoholism: Clinical and Experimental Research
Journal of Neuroscience
Drug and Alcohol Dependence
Bioorganic Medicinal Chemistry Letters
Neuropharmacology
Journal of Neuroscience
Nicotine & Tobacco Research
D. Peer Review Committee
National Science Foundation (ad hoc, 1990, 1996, 1998)
Special Review Committee for the National Institute of Alcohol Abuse and
Alcoholism (ADAMHA) Small Instrumentation Program (1992)
Canada Council Killam Research Fellowship (1993)
National Institute on Drug Abuse:
Drug Abuse Biomedical Research Review Committee Pharmacology III
Research Subcommittee (June & October 1994; February 1995; ad hoc)
Basic Behavioral Sciences Res Subcommittee (SRCD-F-26) (November
1995; ad hoc)
Basic Behavioral Sciences Res Subcommittee (NIDA-D) (1996-1999;
member)
Division of Treatment Research Development, In Vitro Contracts Consultant
(October 2000)
Special Emphasis Panel (SEP PO1; July 2000; member)
Special Emphasis Panel (SEP ZRG1-SSS P01; August 2002, member)
Behavioral Science Track Awards for Rapid Transition Review Committee
(ZDA1-JXP-R) (July 2001)
Division of Treatment Research Development, Contract Review (September
2003)
National Institute on Drug Abuse/Veterans Administration: Cocaine Treatment
Discovery Program and Methamphetamine Treatment Discovery Program
(November 2003)
Division of Treatment Research Development, Contract Review RFP No1DA4-8849 (June 2004)
National Institute on Drug Abuse Medications Development Reseach
Subcommittee (NIDA-L) (October 2005, ad hoc)
National Institute on Drug Abuse Training Grant Subcommittee (NIDA-K)
(March 2006, ad hoc)
National Institutes of Health:
National Institute of Health DRG Special Study Section (1993)
Linda P. Dwoskin
Curriculum Vitae
Page 11
Integrative, Functional and Cognitive Neuroscience 1 Committee (IFCN-1)
(June 1998-June 2000, member; February, June and October 2002, ad
hoc; February 2003, ad hoc; October 2004 ad hoc)
Integrative, Functional and Cognitive Neuroscience 403 Committee
(IFCN403) (November 2000; member)
Integrative, Functional and Cognitive Neuroscience A Committee (IFCN-A
ZRG1) (September 2004, member; June 2005, member; November 2005
Chairman; March, 2006, member; October, 2006, member)
Drug Abuse ZRG1 IFCN A (03) (September 2004)
Mental Health ZMH1 ERB-N (02) (S) (October 2006, member)
Neurobiology of Motivated Behaviors (NMB; October 2004; June 2005;
February 2006; October 2006, ad hoc)
NMB Working Group Review (February 2006)
Adult Psychopathology and Disorders of Aging SRG (APDA) (June 2006)
National Institute of Health (NIAAA) ZAA1 CC 14 1 Drug Development in
Alcoholism (November 2007, Chairperson)
National Cancer Institute/National Institute on Drug Abuse:
Tobacco Use Research Center Review Committee (July 1999 and July1999,
member)
Tobacco Use Research Center Review Committee (SEP ZCA1 GRB-1 (01),
P50; June 2004, member)
Tobacco-Related Disease Research Program, University of CA, Grant Review
Committee (March 2001; March 2002; March 2003)
The Wellcome Trust Grant Review (May 1999; March 2000)
Canadian Institutes of Health Research, external reviewer (November 2001)
Minority Biomedical Research Support Program, Tenn State University
(November 2001)
Tobacco and Health Research Institute, Grant Reviewer (March 2002)
Philip Morris External Research Program (October 2002; December 2005)
E. Consultant Activity
Layton Biosciences
Pharmacia Corporation
U.S. World Med
Dr. Rick Bevins, Department of Psychology, University of Nebraska-Lincoln, NIH
Grant DA018114 "Acquired Appetitive Properties of Nicotine" 2004-2009.
Dr. Rae Matsumoto, College of Pharmacy, University of Mississippi, COBRE
Grant, “Center of Research Excellence in Natural Products Neuroscience”,
External Advisory Committee, 2005-2010.
Dr. Maureen Keller-Wood, Department of Pharmacodynamics, University of
Florida, Graduate Program Review, 2008
F. University Service
March 1989 Participant in Drug Awareness Month - Lectured to 350
undergraduates in Biology 104, Title: "Ecstasy: Freshmen Love It,
Seniors Fear It”
Linda P. Dwoskin
Curriculum Vitae
Page 12
June 1989
Nov. 1992
May 1996
April 1998
Organizer of Continuing Pharmacy Education Program and
Graduate Student Symposium, "Design and Analysis in Pharmacy
Research"
Recruitment for University of Kentucky Graduate Program Science Engineering and Technology Graduate School Fair
Participant in Brain Awareness Week - Spoke to students and
faculty of Maxwell Elementary School (grades 1-4) to increase
awareness of research in Neurosciences and its application to
human health.
XII. Presentations
A. Local
1986
"Modulation of Dopamine Release in Rat Striatal Slices" Department of
Pharmacology, University of Colorado Health Sciences Center, Denver,
CO (May)
1989
“The Effect of Neurotensin Dopamine Release in Rat Striatal Slices"
Department of Physiology and Biophysics, University of Kentucky
(November)
1989
"Metaphit Antagonizes the Effect of PCP and Nomifensine, not
Amphetamine on Endogenous Dopamine Release from Rat Striatal
Slices" Bluegrass Psychopharmacologic Interest Society (January)
1990
"Effect of DSP4 on Dopaminergic Function in the CNS" Graduate Center
Toxicology, University of Kentucky (March)
1990
"Genetic Determinants of the Effect of PCP" Department of Anatomy and
Neurobiology, College of Medicine, University of Kentucky (May)
1990
"Metaphit, an Antagonist of the Effect of PCP?" Department of
Pharmacology, College of Medicine, University of Kentucky (November)
1993
"Effect of Nicotine and its Metabolites on Striatal Dopamine Function"
Division of Medicinal Chemistry, College of Pharmacy, University of
Kentucky (February)
1993
"Psychobiology of Sensation Seeking and Drug Abuse" Center for
Prevention Research, University of Kentucky (February)
1997
“The Role of Nicotine Metabolites in the CNS Effect of Nicotine” Kentucky
Tobacco Board, Lexington, Kentucky (September)
1997
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” Center of Membrane Sciences, University of Kentucky
(December)
1998
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” Department of Pharmacology, University of Kentucky
(February)
2000
“Nornicotine, a Tobacco Alkaloid and Nicotine Metabolite, Contributes to
Tobacco Dependence” Department of Psychology, University of Kentucky
(September)
2001
“Lobeline, a Potential Treatment for Methamphetamine Abuse” Division of
Pharmaceutical Sciences, College of Pharmacy, University of Kentucky
(August)
Linda P. Dwoskin
Curriculum Vitae
Page 13
2003
2003
2004
2005
“Lobeline, a Potential Treatment for Methamphetamine Abuse”
Department of Pharmacology, University of Kentucky (April)
“Lobeline, a Potential Treatment for Methamphetamine Abuse” Behavioral
Sciences Department, University of Kentucky (December)
“Lobeline, a Potential Treatment for Methamphetamine Abuse” Natural
Products Symposium, Colleges of Agriculture and Pharmacy, University of
Kentucky (October)
“Assessment of Nornicoitne as a Novel Pharmacotherapy for Tobacco
Dependence”, Markey Cancer Center, University of Kentucky (December)
B. National
1986
"Modulation of Dopamine Release in Rat Striatal Slices" Emory University,
Atlanta, GA (October)
1988
"Endogenous Dopamine Storage and Release: Presynaptic
Compartmentation and Methods of Evoked Release" Winter Conference
on Brain Research, Steamboat Springs, CO (January)
1990
"Neurotensin-Catecholamine Interactions: Neurochemical and Behavioral
Correlates of a Very Intriguing Peptide" Winter Conference on Brain
Research, Snowmass, CO (January)
1990
"Metaphit, an Antagonist of the Effects of PCP?" Department of
Pharmacology and Toxicology, School of Medicine, University of
Louisville, KY (October)
1994
"Lobeline Robustly Increases [3H]Dopamine Release from Rat Striatal
Slices” College on Problems of Drug Dependence, Palm Beach, FL
(June)
1995
"Nornicotine Contribution to the CNS Effect of Nicotine" Department of
Pharmacology and Toxicology, Virginia Commonwealth University,
Medical College of Virginia, Richmond, VA (December)
1996
“Mock IRG -NIDA/CPDD Grant Writing Workshop” College on Problems of
Drug Dependence, San Juan, Puerto Rico (June)
1996
“Further Characterization of a Novel Class of Nicotinic Receptor
Antagonist” College on Problems of Drug Dependence, San Juan, Puerto
Rico (June)
1996
“Pyridino N-Substituted Nicotine Analogues: New Class of Nicotinic
Antagonist” Duke Nicotine Research Conference: Nicotinic Receptor
Subtypes and Novel Ligands, Duke University, Durham, North Carolina
(November)
1997
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” Pfizer, Groton, Conneticut (February)
1997
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” Department of Pharmacology, University of Minnesota, NIDA
Training Grant Summer Retreat, Minneapolis, Minnesota (May)
1997
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” National Institute on Drug Abuse Intramural Research
Program, Baltimore, Maryland (October)
Linda P. Dwoskin
Curriculum Vitae
Page 14
1997
1997
1998
1998
1999
1999
1999
2000
2000
2000
2000
2000
2000
2001
2001
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” College of Pharmacy, University of Florida, Gainesville,
Florida (December)
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” College of Pharmacy, Texas Tech, Amarillo, Texas
(December)
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” Department of Physiology and Pharmacology, Bowman Gray
School of Medicine of Wake Forest University, Winston-Salem, North
Carolina (June)
“Interactions of Lobeline and Nicotine with Amphetamine: In vitro
Dopamine Release and Drug Disrimination in Rats” College on Problems
of Drug Dependence, Scottsdale, Arizona (June)
“Novel Approaches to Smoking Cessation: Different Smokes for Different
Folks” Winter Conference on Brain Research, Snowmass, Colorado
(January)
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonist” International Business Communications Conference, Nicotine
Receptors: Advances in Molecular Pharmacology and Drug Development,
Annapolis, Maryland (May)
“Development of a Novel Class of Subtype-Selective Nicotinic Receptor
Antagonists” Department of Pharmacology, University of Minnesota,
Minneapolis, Minnesota, (May)
“Methamphetamine Addiction Think Tank” Division of Treatment Research
and Development, National Institute on Drug Abuse, Bethesda, Maryland
(January)
“Lobeline, a Potential Treatment for Methamphetamine Abuse” National
Institute on Drug Abuse, Bethesda, Maryland (April)
“A Balanced View of the Pharmacological Treatment of Menopause”
Symposium Organizer, American Society Pharmacology and Experimental
Therapeutics (June)
“Nornicotine, a Tobacco Alkaloid and Nicotine Metabolite, Contributes to
Tobacco Dependence” Transdisciplinary Center for Tobacco Research,
University of Minnesota, Minneapolis, MN (October)
“Lobeline, a Potential Treatment for Methamphetamine Abuse”
Minneapolis Medical Research Foundation, Hennepin County Medical
Center, Minneapolis, MN (October)
“Pyridino N-Substituted Nicotine Analogs: Potent and Selective
Antagonists at Nicotinic Acetylcholine Receptors” Department of
Pharmacology, University of Tennessee, Memphis, TN (November)
“Neurochemical and Behavioral Evaluation of Novel Treatments for
Smoking Cessation” Pharmacia Corporation, Kalamazoo, MI (June)
“The Development of Novel Treatments for Psychostimulant Abuse”
Department of Pharmacology, University of Tennessee, Memphis, TN
(August)
Linda P. Dwoskin
Curriculum Vitae
Page 15
2001
2002
2002
2002
2003
2003
2003
2003
2003
2004
2005
2006
2006
2006
2006
2006
“Lobeline, a Potential Treatment for Methamphetamine Abuse” Intramural
Research Program of the National Institute on Drug Abuse, Baltimore, MD
(December)
“Bupropion Treatment of Nicotine Dependence: Perspectives on
Mechanisms of Action” Society for Research on Nicotine and Tobacco,
Savannah, GA (February)
“Advances in the Pharmacology of Breast Cancer” Symposium Organizer,
Experimental Biology 2002, New Orleans, LA (April)
“Pharmacological Approaches to Nicotine Addiction: Discovery” NCI,
NIDA, NIAA Working Group Meeting, Bethesda, Maryland (October)
“Drug Abuse as a Gender Issue” Symposium Organizer and Chair,
Experimental Biology 2003, San Diego, CA (April)
“Presentation Skills” Workshop Participant, Experimental Biology 2003,
San Diego, CA (April)
“Development of a Pharmacotherapy for Tobacco Cessation: bPiDDB, a
Potent and Selective 3/6/2 Nicotinic Receptor Antagonist”, Neuronal
Nicotinic Receptors and Ligands: Targets for Medication, National Institute
on Drug Abuse, Bal Harbour, FL (June)
“Development of Novel Nicotinic Receptor Ligands for Therapies” In:
Nicotine and Nicotinic Receptors – Potential for Parkinson’s Disease
Therapy, Symposium Speaker, Society for Neuroscience, New Orleans,
LA (November)
“Biochemistry and Behavioral Pharmacology of Lobeline” VMAT2
Blockade and Methamphetamine: Implications for Medications
Development, Symposium Speaker, NIDA, Bethesda, MD (December)
“Development of Novel Treatments for Nicotine Addiction” Symposium
Co-Chair and Speaker, American Association of Pharmaceutical
Scientists, Baltimore, MD (November)
“The Development of Lobeline as a Pharmacotherapy for
Methamphetamine Abuse” Department of Psychology, University of Illinois
at Urbana-Champaign, Champaign, IL (March)
“Development of Novel Nicotinic Receptor Antagonists as Treatments for
Nicotine Addiction”, NCDDG Synthesis Meeting, Society on Research on
Nicotine and Tobacco, Orlando FL (February)
“Development of Novel Treatments for Nicotine Addiction”, Department of
Pharmacology, Howard University, Washington D.C. (March)
“The Development of Lobeline as a Pharmacotherapy for
Methamphetamine Addiction”, Department of Pharmacology, University of
Michigan, Ann Arbor, MI (March)
“New Therapeutic Candidates for Smoking Cessation”, University of
Michigan Substance Abuse Research Center, University of Michigan, Ann
Arbor MI (March)
“Development of Novel Treatments for Nicotine Addiction”, Department of
Psychological and Brain Sciences, Programs in Neuroscience and
Cognitive Science, Indiana University, Bloomington, IN (March)
Linda P. Dwoskin
Curriculum Vitae
Page 16
2006
2006
2006
2007
2007
2007
2007
2007
2008
C.
1991
1993
1999
2000
2005
“The Development of Lobeline and its Analogs as Potential
Pharmacotherapies for Methamphetamine Addiction”, Distinguished
Lecturer, Department of Psychology, Boston University, Boston, MA (April)
“The Development of Lobeline and its Analogs as Potential
Pharmacotherapies for Methamphetamine Addiction”, Department of
Pharmacology and Toxicology, University of Arkansas for Medical
Sciences, Little Rock, Arkansaw, (April)
“Developments in Methamphetamine Abuse: Targets and
Pharmacotherapies” Symposium Organizer and Speaker, College on
Problems of Drug Dependence, Scottsdale, Arizona (June)
“Development of Novel Treatments for Nicotine and Methamphetamine
Addiction” Ohio State University, (January)
“Environmental Enrichment Alters Dopamine Transporter and Vesicular
Monoamine Transporter Function and Cellular Localization.” Keystone
Symposia Neurobiology of Addiction, Santa Fe, New Mexico (February)
“The Motivational Impact of Nicotine and its Role in Tobacco Use" 55th
Nebraska Symposium on Motivation, University of Nebraska-Lincoln,
Lincoln, Nebraska (April)
“The Development of Lobeline and its Analogs as Potential
Pharmacotherapies for Methamphetamine Addiction” Oregon Health
Sciences University, Portland, Oregon (June)
“Development of Novel Treatments for Nicotine Addiction”, Department of
Pharmacology, Emory University, Atlanta, GA (November)
“Development of Novel Treatments for Nicotine Addiction”, Department of
Pharmacology, Univ New Mexico, Albuquerque, NM (March)
International
"Genetic Isolation of In Vivo and In Vitro PCP Responsiveness" Third
French-U.S. Seminar, Multiple Sigma and PCP Receptor Ligands:
Mechanism for Neuromodulation and Neuroprotection? LaGrande Motte,
France (September)
"Genetic Approaches to Studying Behavioral and Neurochemical
Sensitivity to Psychoactive Drugs" Winter Conference on Brain Research,
Whistler, B.C., Canada (January)
“Emerging Biological Targets for the Treatment of Nicotine Dependence”
Symposium Organizer and Speaker, College on Problems of Drug
Dependence, Acapulco, Mexico (June)
“Nornicotine, a Tobacco Alkaloid and Nicotine Metabolite, Contributes to
Tobacco Dependence” 11th World Conference on Tobacco OR Health,
Chicago, IL (August)
“Pharmacology of the Bis-picolinium analog, bPiDDB: A Lead Compound
for the Development of Novel Subtype-selective Nicotinic Receptor
Antagonists as Treatments for Smoking Cessation.” Society for Research
on Nicotine and Tobacco and Annual SRNT European Conference,
Prague, Czech Republic (March)
Linda P. Dwoskin
Curriculum Vitae
Page 17
2005
2007
“Individual Differences in Nicotine-Induced Hyperactivity and NicotineInduced Augmentation of Dopamine Transporter Function and Trafficking
to the Cell Surface in Prefrontal cortex in Rats. 11th Biennial Eurpoean
Behavioural Pharmacology Society Meeting, Barcelona, Spain
(September)
“Building Translational Research in Medication Development in Academia:
Issues, Strategies and Tactics” College on Problems on Drug
Dependence, Quebec City, Canada (June)
D. Media Events
Lexington Herald Leader, lead article: "Plant Possible Addiction Treatment", Oct.
30th, 2000, page C5.
http://www.kentuckyconnect.com/health/stories/features/1030lobeline.htm
University of Kentucky. “2002 Research Highlights” “Changing Nicotine to Fight
Disease and Drug Addiction” and “Novel Therapies for Methamphetamine
Abuse”. p. 10, 2002.
Lexington Herald Leader, article: “It’s All About the e’s”, Section C, January 27 th,
2003.
National Institute on Drug Abuse: “Director’s Report to the National Advisory
Council on Drug Abuse”, February, 2003.
http://www.drugabuse.gov/Dirreports/Dirrep203/DirectorReport1.html
Lexington Herald Leader, lead article: “Cures and Currency: Success Story
Inspires Hope for UK-Business Partnerships”, March 9th, 2003, page A13.
http://www.kentucky.com/mld/heraldleader/5351696.htm
University of Kentucky: Odyssey Online Exclusive. “Faculty Entrepreneurs Linda
Dwoskin and Peter Crooks: Research Findings to Crow About”. October 14 th,
2003. http://www.rgs.uky.edu/ca/odyssey/exclusive/index.html
Louisville Courier Journal: “Kentucky Puts Hopes in Natural-Products Sector”.
November 9th, 2003.
http://www.courierjournal.com/business/news2003/11/09/biz-front-natural096013.html
University of Kentucky Press Release; "Nicotine is Focus of Record Grant”.
November 13th, 2003, http://www.uky.edu/PR/News/03-11_nicotine_grant.htm
WKYT (CBS Lexington) Mid-day and Evening News, November 13th, 2003; "UK
Receives Record Grant to Study New Treatments for Nicotine Addiction”.
WLEX (NBC Lexington) Mid-day and Evening News, November 13th, 2003; “UK
Professors get $6 Million Grant to Develop New Drugs for Nicotine Addiction”.
WLKY (NBC Louisville) Mid-day and Evening News, November 13th, 2003; “UK
Researchers Get Record Grant to Study Nicotine Addiction”.
Linda P. Dwoskin
Curriculum Vitae
Page 18
Lexington Herald Leader, front page story: "UK Gets $6 Million to Help Kick
Nicotine: Grant Award is Boost for College ", November 13th, 2003.
http://www.kentucky.com/mld/kentucky/news/7259103.htm
The Louisville Courier Journal, front page story: “UK Effort on Quitting Smoking
Wins Grant: Researchers’ Drug Aims to Stop Craving Without Nicotine”,
November 13th, 2003. http://www.courier-journal.com/localnews/2003/11/14ky/
met-front-grant1114-5650.html
Kentucky Kernel: “Researchers get Record Grant: $6 Million Grant Helps College
of
Pharmacy
Study
Nicotine,
Tobacco”,
November
13 th,
2003.
http://www.kykernel.com/
UK News: “Pharmacy gets Record Grant”, November 24th, 2003.
http://www.uky.edu/PR/UK_News/welcome.html
The Philidelphia Inquirer: “Making Drugs on Slim Budget: A Biotech Start-up
that’s Making New Drugs with Little Capital”. December 5th, 2005.
www.philly.com
Chemical and Engineering News: Cover story “Drugs to Fight Addictions”,
September 25, 2006, Vol 84, No 39, pp. 21-44.
http://pubs.acs.org/email/cen/html/092606172455.html
XIII. Research Productivity
A. Research Projects
My laboratory’s research focus is drug discovery in the field of
neuropharmacology, specifically the development of novel treatments for
psychostimulant drug abuse. Drugs within the psychostimulant class being
investigated include nicotine, amphetamine, methamphetamine and cocaine.
Novel analogs are synthesized by our collaborators, and subsequently, their
mechanism of action is elucidated in my laboratory. The ability of these novel
drugs to modulate dopaminergic neuronal function is a focus as the
dopaminergic system has been implicated in reward and reinforcement obtained
during self-administration of drugs of abuse. Techniques employed in this regard
include dopamine release, dopamine metabolism and dopamine reuptake or
clearance using rodent brain slices, synaptosomes and synaptic vesicles,
dopamine autoreceptor function, as well as heterologous modulation by other
neurotransmitter function. Dopaminergic presynaptic terminal function in
striatum, nucleus accumbens and prefrontal cortex is primarily studied. We also
study the effects of psychostimulants and potential therapeutic agens using
whole animal models to study their neurochemical effects, using in vivo
voltammetry. In the process of therapeutic development, lead analogs from the
neurochemical assays are tested to determine their effects on behavior using
whole animal models. Analogs are tested in locomotor activity assays,
specifically to determine if they block the stimulant effects of these abused drugs.
Linda P. Dwoskin
Curriculum Vitae
Page 19
Promising therapeutic candidates are also tested using operant behavior in the
lab of our collaborators to determine if they inhibit the intravenous selfadministration of the stimulant drugs of abuse. In another very important ongoing
project, the role of genetic factors and environmental factors as determinants of
individual responsiveness to drugs of abuse and as determinants of an
individual’s potential for abuse liability are also a focus of my laboratories
research.
B. Current Research Support
NIH U19DA017548 NCDDG “Development of Novel Treatments for Nicotine
Addiction”, Project Director and PI: L.P. Dwoskin (45% Effort), co-PIs: P.A.
Crooks, M.T. Bardo, annual direct costs, $911,490 (total direct costs,
$4,784,294), 09/30/03 – 06/30/08. An integrative approach, including medicinal
chemistry, pharmacokinetics, metabolism, pharmacology, psychology and
neuroscience, is being used to increase our understanding of the underlying
mechanisms of tobacco use and nicotine addiction, with focus on the
development of subtype-selective nicotinic receptor antagonists as
pharmacotherapeutic candidates for the treatment of nicotine addiction.
NIH RO1 DA 13519-05 “Development of Novel Therapies for Methamphetamine
Abuse” PI: L.P. Dwoskin (20% effort), co-PIs: P.A. Crooks, M.T. Bardo, annual
direct costs, $362,838 (total direct costs, $1,955,243), 09/01/06-08/31/11. This
project will determine the structure activity relationships for lobeline interaction
with neurotransmitter transporters.
NIH R21 DA018372-01, “Nicotinic Receptor Regulation of Dopamine
Transporter” PI: L.P.Dwoskin (10% effort), annual direct costs $150,000 (total
direct costs, $275,000), 09/30/05-08/31/08. This project focuses on studying the
regulation of dopamine transporter trafficking by nicotinic receptors.
KTRDC, “Lobeline: preclinical studies” PI: L.P. Dwoskin (5% effort), (total direct
costs, $60,000), 01/01/08-12/31/09. This project focuses on the effects of
lobeline in an animal model of ADHD.
NIH RO1 DA12964-04 “Novelty, Dopamine and Response to Amphetamine” PI:
M.T. Bardo, co-PI: L.P. Dwoskin (10% effort), annual direct costs, $294,600
(total direct costs, $698,732), 11/01/03-10/31/08. The goal of this project is to
assess the effect of raising rats in an enriched environment during development
on amphetamine self-administration. Neural correlates will be examined using in
vivo and in vitro neurochemical assays.
NIH R21 DA021199 “Prenatal Nicotine, Behavioral Teratogenicity and
Dopamine” PI: J.R. Pauly; co-PI: L.P.Dwoskin (7.5% effort), M. McIntosh,
annual direct costs, $125,000 (total direct costs, $275,000), 09/25/06-08/31/08.
This project will identify neurochemical mechanisms that underlie nicotine
induced changes in neuropsychological development.
Linda P. Dwoskin
Curriculum Vitae
Page 20
NIH P50 DA05312 “CDART – Center for Drug Abuse Research Translation”,
M.T. Bardo, PI, annual direct costs, $756,504 (total direct costs, $3,622,664),
Project 1, PI: M.T. Bardo; co-PI: L.P. Dwoskin (15% effort), 09/31/07-06/30/12.
The goal of the Center is to investigate how environmental context affects interand intra-individual differences in reward seeking and inhibition as it relates to
drug abuse prevention.
KTRDC Research program in plant derived natural products. “Subtype-selective
drugs for nicotinic receptors from Kentucky native plants” PI: J. Littleton, co-PI:
L.P.Dwoskin (0% effort), co-PI: P.A. Crooks, annual direct costs $89,943,
07/01/06 – 06/30/07. This proposal is to begin to identify the active compounds
in Kentucky native plants and to characterize these with a view to
commercialization.
HRD-0217196R25, “National Science Foundation, Girls in Science”, P.I.
Leukefeld, Instructor/Mentor: L.P. Dwoskin (2% effort), annual direct costs
$270,000, 05/01/03-06/30/07. This project is to encourage young girls from SE
Kentucky to pursue careers in science, math, engineering and technology.
Dwoskin serves as a Summer Instructor/Mentor.
AHA 715489B, “The role of angiotensin in nicotine reward and nicotine-induced
Hypertension”, Fellowship to Vidya Narayanaswami; Faculty mentor: L.P.
Dwoskin, (total direct costs, $42,000), 07/01/07-06/30/09.
NIDA T32 DA16176, “Training in Drug Abuse Related Research” PI: L.B. Hersh,
co-Director; L.P. Dwoskin (annual direct costs, $194,154; total direct costs,
$1,073,634), 7/01/04 - 6/30/09.
NIDA T32 DA 07304, “Research Training in Drug Abuse Behavior”, P.I. T.F.
Garrity, Faculty mentor: L.P. Dwoskin, annual direct costs $148,525 (total
direct costs, $782,836), 7/01/98 - 6/30/08.
NIEHS ES 07266 “Molecular Mechanisms of Toxicity Training Grant” PI: M. Vore,
Faculty mentor: L.P. Dwoskin, $193, 593 (total direct costs = $930,125),
07/01/05 - 6/30/09.
NIEHS R25 ES016248-01 “Summer Education Experience in Research in
Toxicology (STEER)” PI: M. Vore, Faculty mentor: L.P. Dwoskin, (total direct
costs, $170,800) 11/01/07-10/31/12.
C. Pending Research Support
NIH 2RO1 DA013144-06 “Methamphetamine and HIV Protein-induced
Neurotoxicity” PI: William F. Maragos (5% effort), annual direct costs $259,580
(total direct costs, $1,270,066), 04/01/07-3/30/12. Proposed studies focus on the
influence of HIV Tat in the toxicity associated with methamphetamine abuse.
Linda P. Dwoskin
Curriculum Vitae
Page 21
NIH U19 PAR-07-159 NCDDG “Development of Novel Treatments for Nicotine
Addiction”, Project Director and PI: L.P. Dwoskin (40% Effort), co-PIs: P.A.
Crooks, M.T. Bardo, annual direct costs, $1,008,215 (total direct costs,
$5,352,757), 07/01/08 – 06/30/13. An integrative approach, including medicinal
chemistry, pharmacokinetics, metabolism, pharmacology, psychology and
neuroscience, will be used to increase our understanding of underlying
mechanisms of nicotine addiction and focusing on development of subtypeselective nicotinic receptor antagonists as therapeutic candidates for the
treatment of nicotine addiction.
NIH/NIDA R01 DA12964, “Novelty, dopamine and response to amphetamine”,
PI: M. Bardo (total direct costs, $1,250,000) 07/01/08-06/30/13. This project will
assess the effect of raising rats in an enriched environment during development
on amphetamine self-administration and underlying neurochemical mechanisms.
Parenteral Drug Association Pre-Doctoral Fellowship Program, “The effect of
acute and chronic in vivo administration of lobeline and methylphenidate on
vesicular monoamine transporter function” Thte purpose of this fellowship is to
encourage outstanding pre-doctoral students to continue their studies and earn
the Ph.D. in Pharmacuetical science or a related field and to promote applied
research in areas of study relevant to the scientific foundations of pharmaceutical
product development, drug manufacturing and quality assurance technologies.
(total costs $80,000) 06/01/08 – 05/31/09 Faculty mentor: L.P. Dwoskin
D. Completed Research Projects (last 5 years)
NIH KO2 DA00399 “Development of Selective Nicotinic Receptor Antagonists”,
PI: L.P. Dwoskin (75% Effort), annual direct costs, $108,285 (total direct costs,
$425,903), 07/01/99 - 06/30/04.
NIH P20 RR15592 “Center of Biomedical Research Excellence (COBRE) in
Women’s Health” PI: Thomas Curry, Ph.D., total direct costs $7,449,972. Pilot
Project: Estrous Cycle Phase Regulation of Nicotine-Evoked Dopamine Release:
Neurochemical Mechanism Underlying Dependence Upon Tobacco Smoking; PI:
L. P. Dwoskin (5% effort), 09/01/02 - 08/31/04.
NIH F31 DA 15292 NRSA Predoctoral Fellowship “Nicotinic Receptor Regulation
of Dopamine Transporters” PI: L. S. Middleton, Sponsor: L.P. Dwoskin, annual
direct costs = $26,000 (total direct costs, $52,000), 01/01/02-12/31/04
NIH STTR R41 DA016521 “Nornicotine Enantiomers and Nicotine SelfAdministration” PI: M.T. Bardo, co-PI: L.P. Dwoskin (5% effort), annual direct
costs $100,000 (total direct costs, $149,000), 07/01/03-12/31/03.
Linda P. Dwoskin
Curriculum Vitae
Page 22
NIH RO1 DA 10934, “Development of Selective Nicotinic Receptor Antagonists”,
PI: L.P. Dwoskin, Co-PI: P.A. Crooks, Co-PI: J. Pauly, annual direct costs,
$141,393 (total direct costs, $600,421), 01/15/98-12/31/02.
NIH F32 DA 06043 NRSA Postdoctoral Fellowship “Lobeline, a Potential Therapy
for Methamphetamine Abuse” PI: D.K. Miller, Sponsor: L.P. Dwoskin, total
direct costs = $71,112, 08/15/00-08/14/02.
NIH RO1 HL 58927-04, “Angiotensin, Leptin, and the Sympathetic Nervous
System, PI: L.A. Cassis, co-PI: L.P. Dwoskin, R.L. Lodder, annual direct costs,
$126,501 (total direct costs, $382,298), 07/01/98-06/30/02.
Tobacco and Health Research Institute Grant. "CNS Pharmacology of Lobelia
Inflata Alkaloids and Related Compounds," PI: L.P. Dwoskin, Co-PI: P.A.
Crooks, 07/01/01 - 06/30/02, annual direct costs = $50,345 (total direct costs,
$768,108, eleventh year renewed, since 07/01/90).
Targacept Inc., “Synthesis of Compounds as Therapeutic Agents in Alzheimer’s
Disease.” PI: P.A. Crooks; Co-PI: L.P.Dwoskin, direct costs; $118,386 (total
costs, $149,167); 1/16/02-1/15/03.
NIH “Building Interdisciplinary Research Careers in Women’s Health (BIRCWH)”,
P.I. Emery Wilson, M.D., Faculty mentor: L.P. Dwoskin, total direct costs
$2,500,000; 2000-2005.
NIH NIH K30 HL004163 “Career Training in Therapeutics and Translation
Research”, P.I. Shedlofsky, S.,Faculty mentor: L.P. Dwoskin, 2001-2005.
NIH R25 DA11388, “Female Drug Abuse Science Curriculum”, PI: C. Leukefeld,
Faculty mentor: L.P. Dwoskin (1.9% effort), annual direct costs, $197,021 (total
direct, $435,845), 7/01/98 - 06/30/04.
E. Publications
1.
Wayner M.J., Singer G., Cimino K., Stein J. and Dwoskin L.P. Adjunctive
behavior induced by different conditions of wheel running. Physiol. Behav.
14:507-510, 1975.
2.
Kantak K.M., Wayner M.J., Tilson H.A., Dwoskin L.P. and Stein J.M.
Synthesis and turnover of 3H-5-hydroxytryptamine in the lateral
cerebroventricle. Pharmacol. Biochem. Behav. 8:153-161, 1978.
3.
Dwoskin L.P., Sprague, G.L., Takemori, A.E. and Sparber, S.B. Morphine
release and displacement by naloxone in vivo in morphine naive and
morphine withdrawn rats. Life Sci. 26:377-385, 1980.
4.
Dwoskin L.P. and Sparber S.B. Comparison of yohimbine, mianserin,
chlorpromazine and prazosin as antagonists of the suppressant effect of
clonidine on operant behavior. J. Pharmacol. Exp. Ther. 226:57-64, 1983.
Linda P. Dwoskin
Curriculum Vitae
Page 23
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Dwoskin L.P. and Sparber S.B. Behaviorally inactive doses of mianserin
antagonize the suppressant effect of lysergic acid diethylamide on a fixed
ratio operant. J. Pharmacol. Exp. Ther. 225:77-84, 1983.
Dwoskin L.P., Neal B.S. and Sparber S.B. Yohimbine exacerbates and
clonidine attenuates acute morphine withdrawal in rats. Eur. J. Pharmacol.
90:269-273, 1983.
Kleven M., Dwoskin L.P. and Sparber S.B. Pharmacological evidence for
the existence of multiple functional pools of brain serotonin: Analysis of
brain perfusate from conscious rats. J. Neurochem. 41:1143-1149, 1983.
Sparber S.B., Dwoskin L.P. and Kleven M.S. Studies on the specificity of
the neurochemical and behavioral effects of LSD-25. Pharmacol. Biochem.
Behav. 24:341-345, 1986.
Dwoskin L.P. and Zahniser N.R. Robust modulation of 3H-dopamine
release from rat striatal slices by D-2 dopamine receptors. J. Pharmacol.
Exp. Ther. 239:442-453, 1986.
Dwoskin L.P., Peris J., Yasuda R.P., Philpott K. and Zahniser N.R.
Repeated cocaine administration results in supersensitivity of striatal D-2
dopamine autoreceptors to pergolide. Life Sci. 42:255-262, 1988.
Peris J., Dwoskin L.P. and Zahniser N.R. Biphasic modulation of evoked
3H-D-aspartate release by D-2 dopamine receptors in rat striatal slices.
Synapse 2:450-456, 1988.
Dwoskin L.P., Yasuda R.P. and Zahniser N.R. Irreversible inhibition of rat
striatal dopamine uptake induced by in vitro exposure to DSP4. Biochem.
Pharmacol. 38:549-551, 1989.
Gerhardt G.A., Dwoskin L.P. and Zahniser N.R. Outflow and overflow of
picogram levels of endogenous dopamine and DOPAC from rat striatal
slices: improved methodology for studies of stimulus-evoked release and
metabolism. J. Neurosci. Meth. 26:217-227, 1989.
Dwoskin L.P., Neal B.S. and Sparber S.B. Evidence for antiserotonergic
properties of yohimbine. Pharmacol. Biochem. Behav. 31:321-326, 1989.
Peris J., Boyson S.J., Cass W.A., Curella P., Dwoskin L.P., Larson G., Lin
L.H., Yasuda R.P. and Zahniser N.R. Persistence of neurochemical
changes in dopamine systems after repeated cocaine administration. J.
Pharmacol. Exp. Ther. 253:38-44, 1990.
Cassis L.A. and Dwoskin L.P. Presynaptic modulation of neurotransmitter
release by endogenous angiotensin II in brown adipose tissue. J. Neural
Transm. [Suppl.] 34:129-137, 1991.
Dwoskin L.P., Jewell A.L. and Cassis L.A. DuP 753, a nonpeptide
angiotensin II-1 receptor antagonist, alters dopamine function in rat striatum.
Naunyn Schmiedebergs Arch. Pharmacol. 345:153-159, 1992.
Dwoskin L.P., Leibee L.L., Jewell A.L., Fang Z.X. and Crooks P.A.
Inhibition of [3H]-dopamine uptake into rat striatal slices by quaternary Nmethylated nicotine metabolites. Life Sci. 50:PL233-PL237, 1992.
Dwoskin L.P., Jewell A.L., Buxton S.T. and Carney J.M. Phencyclidineinduced desensitization of striatal dopamine release. Neuropharmacology
31:1033-1039, 1992.
Linda P. Dwoskin
Curriculum Vitae
Page 24
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
Soltis E.E., Jewell A.L., Dwoskin L.P. and Cassis L.A. Acute and chronic
effects of losartan (DuP 753) on blood pressure and vascular reactivity in
normotensive rats, Clin. Exp. Hypertens. 15:171-184, 1993.
Dwoskin L.P., Buxton S.T., Jewell A.L. and Crooks P.A. S(-)Nornicotine
increases dopamine release in a calcium-dependent manner from rat striatal
slices. J. Neurochem. 60:2167-2174, 1993.
Jewell A.L., Wedlund P.J. and Dwoskin L.P. Strain differences in rat brain
and liver sigma binding: lack of cytochrome P450-2D1 involvement. Eur. J.
Pharmacol. 243:249-254, 1993.
Jewell A.L., Carney J.M. and Dwoskin L.P. Inherent differences in brain
regional content of dopamine and serotonin in two inbred mouse strains
differentially sensitive to phencyclidine. NIDA Res. Monograph 140:248,
1993.
Dwoskin L.P., Buxton S.T., Teng L. and Crooks P.A. Nornicotine-induced
dopamine (DA) release from rat striatal slices is concentration-dependent,
calcium-dependent and stereoselective. NIDA Res. Monograph 140:249,
1993.
Cassis L.A. and Dwoskin L.P. Acute and chronic Losartan administration:
Effect on angiotensin II content and modulation of [3H]norepinephrine
release from rat interscapular brown adipose tissue. J. Neural Transm.
98:159-164, 1994.
Dwoskin L.P., Teng L.H., Buxton S.T. and Crooks P.A. Lobeline robustly
increases [3H]dopamine release from rat striatal slices. NIDA Res.
Monograph 153:191, 1994.
Bardo M.T., Bowling S.L., Rowlett J.K., Manderscheid P., Buxton S.T. and
Dwoskin L.P. Environmental enrichment attenuates locomotor
sensitization, but not in vitro dopamine release, induced by amphetamine.
Pharmacol. Biochem. Behav. 51:397-405, 1995.
Dwoskin L.P., Teng L.H., Buxton S.T., Ravard A. and Deo N., Crooks P.A.
Minor alkaloids of tobacco release [3H]dopamine release from superfused
rat striatal slices. Eur. J. Pharmacol. 276:195-199, 1995.
Crooks P.A., Ravard A., Wilkins L.H., Teng L.H., Buxton S.T. and Dwoskin
L.P. Inhibition of nicotine-evoked [3H]dopamine release by pyridino Nsubstituted nicotine analogues: A new class of nicotinic antagonist. Drug
Development Res. 36:91-102, 1995.
Crooks P.A., Li M. and Dwoskin L.P. Determination of nicotine metabolites
in rat brain after peripheral radiolabeled nicotine administration: Detection of
nornicotine. Drug Metab. Disposit. 23:1175-1177, 1995.
Crooks P.A., Wilkins L.H., Teng L.H., Ravard A. and Dwoskin L.P.
Neurochemical characterization of a new class of novel nicotinic receptor
antagonist. NIDA Res. Monograph, 162:286, 1995.
Dwoskin L.P., Wilkins L.H., Crooks P.A., Bradley M.C. and Bardo M.T.
Behavioral sensitization to nornicotine: lack of correlation with [3H]nicotine
binding in rat whole brain. NIDA Res. Monograph 162:311, 1995.
Linda P. Dwoskin
Curriculum Vitae
Page 25
33.
34.
34.
35.
36.
37.
37.
38.
39.
40.
41.
42.
43.
Dwoskin L.P., Damaj M.I., Allen D.D., Wilkins L.H. and Crooks P.A. Further
characterization of a novel class of nicotinic receptor antagonists. NIDA
Res. Monograph 174:65, 1996.
Crooks P.A., Wilkins L.H., Teng L.H., Ravard A. and Dwoskin L.P.
Neurochemical characterization of a new class of novel nicotinic receptor
antagonist. NIDA Res Monograph 162:286, 1996.
Crooks P.A., Teng L.H., Li M., Bardo M.T., Wilkins L.H. and Dwoskin L.P.
Cotinine pharmacology: Brain uptake and metabolism, effects on dopamine
release and lack of behavioral sensitization after chronic administration to
rats. NIDA Res. Monograph 174:203, 1996.
Teng L-H., Crooks P.A., Sonsalla P.K. and Dwoskin L.P. Lobeline and
nicotine evoke [3H]overflow from rat striatal slices preloaded with
[3H]dopamine: Differential inhibition of synaptosomal and vesicular
[3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280:1432-1444, 1997.
Crooks P.A., Li M and Dwoskin L.P. Metabolites of nicotine in rat brain
after peripheral nicotine administration: Cotinine, nornicotine and
norcotinine. Drug Metab. Dispos. 25:47-54, 1997.
Crooks P.A., Teng L.H., Li M., Bardo M.T., Wilkins L.H., and Dwoskin L.P.
Cotinine Pharmacology: brain uptake and metabolism, effects on dopamine
release and lack of behavioral sensitization after chronic administration to
rats. NIDA Res Monograph 174:203, 1997.
Crooks P.A. and Dwoskin L.P. Contribution of CNS nicotine metabolites to
the neuropharmacological effects of nicotine and tobacco smoking.
Biochem. Pharmacol. 54:743-753, 1997.
Weed M.R., Paul I.A., Dwoskin L.P., S.E. Moore and Woolverton W.L. The
relationship between reinforcing effects and in vitro effects of D1 agonists in
monkeys. J. Pharmacol. Exp. Ther. 283:29-38, 1997.
Teng L.H., Crooks P.A., Buxton S.T. and Dwoskin L.P. Nicotinic-receptor
mediation of S(-)nornicotine evoked [3H]overflow from rat striatal slices
preloaded with [3H]dopamine. J. Pharmacol. Exp. Ther. 283:778-787, 1997.
Bardo M.T., Bevins R.A., Klebaur J.E., Crooks P.A. and Dwoskin L.P. (-)Nornicotine partially substitutes for (+)-amphetamine in a drug
discrimination paradigm in rats. Pharmacol. Biochem. Behav., 58:10831087, 1997.
Teng L.H., Crooks P.A. and Dwoskin L.P. Lobeline displaces
[3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat
striatal synaptic vesicles: Comparison with d-amphetamine. J. Neurochem.
71:258-265, 1998.
Cassis L., Laughter A., Fettinger M., Akers S., Speth R., Burke G., King V.
and Dwoskin L.P. Cold exposure regulates the renin-angiotensin system.
J. Pharmacol. Exp. Ther. 286:718-726, 1998.
Dwoskin L.P., Acri J.B., Crooks P.A., Teng L.H. and Witkin J.M.
Interactions of lobeline and nicotine with amphetamine: In Vitro DA release
and drug discrimination in rats. NIDA Res. Monograph 179:68, 1998.
Linda P. Dwoskin
Curriculum Vitae
Page 26
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
Crooks P.A., Ghosheh O. and Dwoskin L.P. Increased concentrations of
plasma cotinine in schizophrenic smokers compared to normal smokers.
NIDA Res. Monograph 179:192, 1998.
Dwoskin L.P., Teng L.H., Buxton S.T. and Crooks P.A. S(-)Cotinine, the
major brain metabolite of nicotine, stimulates nicotinic receptors to evoke
[3H]dopamine release from rat striatal slices in a calcium-dependent
manner. J. Pharmacol. Exp. Ther. 288:905-911, 1999.
King V.L., Dwoskin L.P. and Cassis L.A. Cold exposure regulates the
norepinephrine uptake transporter in rat brown adipose tissue. Amer. J.
Physiol. 276:R143-R151, 1999.
Bardo M.T., Valone J.M., Robinet P.M., Shaw W.B. and Dwoskin L.P.,
Environmental enrichment enhances the stimulant effect of intravenous
amphetamine: Search for a cellular mechanism in the nucleus accumbens.
Psychobiology 27:292-299, 1999.
Dwoskin L.P., Wilkins L.H., Pauly J.R. and Crooks P.A. Development of a
novel class of subtype selective nicotinic receptor antagonist: Pyridine Nsubstituted nicotine analogs. Volume: Molecular and Functional Diversity of
Ion Channels and Receptors. Ann. N.Y. Acad. Sci. 868:617-619, 1999.
Dwoskin L.P., Crooks P.A., Teng L-H., Green T.A. and Bardo M. Acute
and chronic effects of nornicotine on locomotor activity in rats: Altered
response to nicotine. Psychopharmacology 145:442-451, 1999.
Bardo M.T., Green T.A., Crooks P.A. and Dwoskin L.P. Nornicotine is
self-administered intravenously by rats. Psychopharmacology 146:290-296,
1999.
Ghosheh O., Dwoskin L.P. and Crooks P.A. Residence time and half-lives
of nicotine metabolites in rat brain after acute peripheral administration of
[2'-14C]nicotine. Drug Metab. Dispos. 27:1448-1455, 1999.
Shafaee N., Houng M., Truong A., Viseshakut N., Figl A., Sandhu S.,
Forsayeth J.R., Dwoskin L.P., Crooks P.A. and Cohen B.N.
Pharmacological differences between native brain and heterologously
Br. J. Pharmacol. 128:1291-1299,
1999.
Maragos W.F., Jakel R.J., Chesnut M.D., Geddes J.W. and Dwoskin L.P.
Does dopamine contribute to striatal damage caused by impaired
mitochondrial function? Ann. N.Y. Acad. Sci. 893:345-349, 1999.
Crooks P.A., Jones M.D., Chesnut M.D., Jaromczyk A.M. and Dwoskin L.P.
Stereochemically defined lobeline analogues: Inhibition of [3H]dopamine
uptake and [3H]nicotine binding in rat striatum. NIDA Res. Monograph
180:234, 1999.
Green T.A., Bardo M.T., Crooks P.A., Haubner A.J. and Dwoskin L.P.
Nornicotine evokes [3H]overflow from rat nucleus accumbens slices
preloaded with [3H]dopamine. NIDA Res. Monograph 180:195, 1999.
Dwoskin L.P. Novel subtype-selective nicotinic receptor antagonist block
the neurochemical effects of nicotine. NIDA Res. Monograph 180:54, 1999.
Ghosheh O.A., Browne D., Rogers T., deLeon J., Dwoskin L.P. and Crooks
P.A. A simple high performance liquid chromatographic method for the
Linda P. Dwoskin
Curriculum Vitae
Page 27
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
quantification of four major nicotine metabolites and caffeine in the plasma
of smokers. J. Pharm. Biomed. Anal. 23:543-549, 2000.
Dwoskin L.P., Xu R., Ayers J. and Crooks P.A. Recent developments in
neuronal nicotinic acetylcholine receptor antagonist. Exp. Opin. Ther.
Patents 10:1561-1581, 2000.
Miller D.K., Crooks P.A. and Dwoskin L.P. Lobeline inhibits nicotineevoked [3H]dopamine overflow from rat striatal slices and nicotine evoked
86Rb+ efflux from thalamic synaptosomes. Neuropharmacology 39:26542662, 2000.
Green T.A., Phillips S.B., Crooks P.A., Dwoskin L.P. and Bardo M.T.
Nornicotine pretreatment decreases intravenous nicotine self-administration
in rats. Psychopharmacology 152:289-294, 2000.
Akers W.S., Cross A., Speth R., Dwoskin L.P. and Cassis L.A.
Compensatory activation of the sympathetic nervous system and the renin
angiotensin system in response to pressure overload. Circ. Res. 279:
H2797-H2806, 2000.
Grinevich V.P., Xu R., Crooks P.A., Haubner A.J., Papke R. and Dwoskin
L.P. Rigid nicotine analogs pr
-containing
neuronal nicotinic acetylcholine receptors. Drug Alcohol Depend. 60:S8081, 2000.
Crooks P.A., Xu R., Grinevich V.P., Haubner A.J. and Dwoskin L.P.
Conformationally restrained analogues of NONI and NDNI are selective
subtype. Drug Alcohol Depend. 60:S46-47, 2000.
Harrod S.B., Klebaur J.E., Phillips S.B., Crooks P.A., Dwoskin L.P. and
Bardo M.T Lobeline noncompetitively inhibits methamphetamine selfadministration in rats. Drug Alcohol Depend. 60:S84-85, 2000.
Miller D.K., Green T.A., Harrod S.B., Bardo M.T., Crooks P.A. and Dwoskin
L.P. Effects of lobeline on methamphetamine and nicotine-induced
hyperactivity and sensitization. Drug Alcohol Depend. 60:S151-152, 2000.
Miller D.K., Crooks P.A., Teng L., Witkin J.M., Munzar P., Goldberg S.R.,
Acri J.B. and Dwoskin L.P. Lobeline inhibits the neurochemical and
behavioral effects of amphetamine. J. Pharmacol. Exp. Ther. 296:10231034, 2001.
Butt C.M., Pauly J.R., Wilkins L.H., Dwoskin L.P. and Debski E.A.
Pharmacology, distribution and development of muscarinic acetylcholine
receptor subtypes in the optic tectum of Rana pipiens. Neurosci. 104:161179, 2001.
Ghosheh O.A., Dwoskin L.P., Miller D.K. and Crooks P.A. Accumulation of
nicotine and its metabolites in rat brain after intermittent or continuous
peripheral administration of [2'-14C]-nicotine. Drug Metab. Dispos. 29:645651, 2001.
Miller D.K., Wilkins L.H., Bardo M.T., Crooks P.A. and Dwoskin L.P. Once
weekly administration of nicotine produces long-lasting locomotor
sensitization in rats via a nicotinic receptor-mediated mechanism.
Psychopharmacology 156:469-476, 2001.
Linda P. Dwoskin
Curriculum Vitae
Page 28
70.
71.
72.
73.
74.
75.
76.
77.
76.
77.
77.
78.
78.
Harrod S.B., Dwoskin L.P., Crooks P.A., Klebaur J.E. and Bardo M.T.  Lobeline attenuates d-methamphetamine self-administration in rats. J.
Pharmacol. Exp. Ther. 298:172-179, 2001.
Dwoskin L.P. and Crooks P.A. Competitive neuronal nicotinic receptor
antagonists: A new direction for drug discovery. J. Pharmacol. Exp. Ther.
298:345-402, 2001.
Xu R., Dwoskin L.P., Grinevich V.P., Deaciuc G. and Crooks P.A.
Neuronal nicotinic acetylcholine receptor binding affinities of boroncontaining nicotine analogs. Bio. Org. Med. Chem. Lett. 11:1245-1248,
2001.
Green T.A., Crooks P.A., Bardo M.T. and Dwoskin L.P. S(-)-Nornicotine
evokes [3H]overflow from rat nucleus accumbens slices preloaded with
[3H]dopamine in a nicotinic receptor-mediated and calcium-dependent
manner. Biochem. Pharmacol. 62:1597-1603, 2001.
Dwoskin L.P., Teng L.H. and Crooks P.A. Nornicotine, a nicotine
metabolite and tobacco alkaloid: desensitization of nicotinic receptorstimulated dopamine release from rat striatum. Eur. J. Pharmacol. 428:6979, 2001.
Truong A., Xing X., Forsayeth J.R., Dwoskin L.P., Crooks P.A. and Cohen
B.N. A pharmacological comparison of immunoisolated native brain and
Mol. Brain Res.
96:68-76, 2001.
Zhu J., Ayers J.T., Ghosheh O., Crooks P.A. and Dwoskin L.P. N-nalkylnicotinium and N-n-alkylpyridinium analogs inhibit [3H]dopamine uptake
into rat striatal synaptosomes. Drug Alcohol Depend. 63:177, 2001.
Crooks P.A., Ayers J.T., Haubner A.J., Grinevich V.P., Sumithran S.P.,
Deaciuc A.G. and Dwoskin L.P. The bis-picolinium salt, bPiDDB, is a
potent and selective antagonist at nicotinic acetylcholine receptors
mediating nicotine-evoked dopamine release in rat striatum. Drug Alcohol
Depend. 64:38, 2002.
Dwoskin L.P. and Crooks P.A. A novel mechanism and potential use for
lobeline as a treatment for psychostimulant abuse. Biochem. Pharmacol.
63:89-98, 2002.
Dwoskin L.P., Miller D.K., Zheng G., Norrholm S.D., Grinevich V.P. and
Crooks P.A. Meso-transdiene, a potent, selective antagonist at alpha3*containing nicotinic receptors. Drug Alcohol Depend. 64:38, 2002.
Maragos W.F., Zhu J., Chesnut M.D. and Dwoskin L.P. Mitochondrial
toxins inhibit [3H]dopamine uptake in rat striatum. Biochem. Pharmacol.
63:1499-1505, 2002.
Norrholm S.D., Miller D.K., Hojahmat M., Crooks P.A. and Dwoskin L.P. 8hydroxyl esterification of lobeline increases selectivity for the apha4beta2*
subtype of nicotinic receptor, while increasing affinity for dopamine and
serotonin transporters. Drug Alcohol Depend. 64:25, 2002.
DeLeon J., Diaz F., Rogers T., Brone D., Dinsmore L., Ghosheh O.,
Dwoskin L.P. and Crooks P.A. Total cotinine in plasma: A stable biomarker
Linda P. Dwoskin
Curriculum Vitae
Page 29
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
for exposure to tobacco smoke. J. Clin. Psychopharmacol. 22:496-501,
2002.
Wilkins L.H., Haubner A., Ayers J. and Crooks P.A. and Dwoskin L.P., N-nAlkylnicotinium analogs, a novel class of nicotinic receptor antagonists:
Inhibition of nicotine-evoked [3H]dopamine overflow from superfused rat
striatal slices. J. Pharmacol. Exp. Ther. 301:1088-1096, 2002.
Miller D.K., Wong E.H.F., Chesnut M.D. and Dwoskin L.P. Reboxetine:
Functional inhibition of monoamine transporters and nicotinic acetylcholine
receptors. J. Pharmacol. Exp. Ther. 302:687-695, 2002.
Xu R., Dwoskin L.P., Grinevich V.P., Sumithran S.P. and Crooks P.A.
Synthesis and evaluation of conformationally restricted pyridino N-alkylated
nicotine analogs as nicotinic acetylcholine receptor antagonists. Drug
Develop. Res. 55:173-186, 2002.
Miller D.K, Sumithran, S.P. and Dwoskin L.P. Bupropion competitively
inhibits [3H]overflow from superfused rat striatal slices preloaded with
[3H]dopamine and from hippocampal slices preloaded with
[3H]norepinephrine. J. Pharmacol. Exp. Ther. 302:1113-1122, 2002.
Green T.A., Brown R.W., Phillips S.B., Dwoskin L.P. and Bardo M.T.
Locomotor stimulant effects of nornicotine: Role of dopamine. Pharmacol.
Biochem. Behav. 74:87-94, 2002.
Rauhut A.S., Mullins S.N., Dwoskin L.P. and Bardo M.T. Reboxetine:
Attenuation of intravenous nicotine self-administration in rats. J. Pharmacol.
Exp. Ther. 303:664-672, 2002.
Miller D.K., Harrod S.B., Green T.A., Wong M.Y., Bardo M.T. and Dwoskin
L.P. Lobeline attenuates the locomotor stimulation induced by repeated
nicotine administration in rats. Pharmacol. Biochem. Behav. 74:279-286,
2002.
Ayers J.T., Dwoskin L.P., Grinevich V.P., Deaciuc A.G. and Crooks P.A.
bis-Azaaromatic quaternary ammonium analogs: Ligands for 42* and 7*
subtypes of neuronal nicotinic receptors. Bio. Org. Med. Chem. Lett.
12:3067-3071, 2002.
DeLeon J., Diaz F., Rogers T., Browne D., Dinsmore L., Ghosheh O.,
Dwoskin L.P. and Crooks P.A. A pilot study of plasma caffeine
concentration in a U.S. sample of smokers and nonsmoker volunteers.
Prog. Neuro-Psychopharmacol. Biol. Psych. 27:165-171, 2003.
DeLeon J., Diaz F., Rogers T., Browne D., Dinsmore L., Ghosheh O.,
Dwoskin L.P. and Crooks P.A. Plasma cotinine, 3’-hydroxycotinine and
their glucuronides in Caucasian and African American smokers . J. Clin.
Psychopharmacol. 23:209-211, 2003.
Wilkins L.H., Grinevich V.P., Ayers J.T., Crooks P.A. and Dwoskin L.P. Nn-Alkylnicotinium analogs, a novel class of nicotinic receptor antagonists:
Interaction with 42* and 7* neuronal nicotinic receptors. J. Pharmacol.
Exp. Ther. 304:401-410, 2003.
Chen J., Norrholm S., Dwoskin L.P., Crooks P.A. and Bai D. N,NDisub
42* and 7*
Linda P. Dwoskin
Curriculum Vitae
Page 30
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
neuronal nicotinic acetylcholine receptors. Bio. Org. Med. Chem. Lett.
13:97-100, 2003.
Harrod S.B., Dwoskin L.P., Green T.A., Gehrke B.J. and Bardo M.T.
Lobeline does not serve as a reinforcer in rats. Psychopharmacology
165:397-404, 2003.
Rauhut A.S., Fenton L., Mullins S.N., Green T.A., Dwoskin L.P. and Bardo
M.T. Effect of acute bupropion pretreatment on intravenous nicotine selfadministration in rats. Psychopharmacology, 169:1-9, 2003.
Allen D.D., Lockman P.R., Roder K.E., Dwoskin L.P. and Crooks P.A.
Active transport of high affinity choline and nicotine analogs into the central
nervous system by the blood brain barrier choline transporter. J.
Pharmacol. Exp. Ther. 304:1268-1274, 2003.
Grinevich V.P., Crooks P.A., Haubner A.J., Ghosheh O.A., Ayers J.T. and
Dwoskin L.P. N-n-alkylpyridinium analogs, a novel class of nicotinic
receptor antagonists: selective inhibition of nicotine-evoked [3H]dopamine
overflow from rat striatal slices. J. Pharmacol. Exp. Ther. 306:1001-1020,
2003.
Zhu J., Ayers J.T., Ghosheh O.A., Sumithran S.P., Crooks P.A. and
Dwoskin L.P. N-n-Alkylnicotinium and N-n-alkylpyridinium analogs inhibit
of dopamine transporter function: Selectivity as nicotinic receptor
antagonists. Drug Dev Res, 60:270-284, 2003.
Zhu J., Green T.A., Bardo M.T. and Dwoskin L.P. Environmental
enrichment enhances GBR12935-induced locomotor sensitization and
decreases dopamine transporter function. Behav. Brain Res., 148:107-114,
2004.
Middleton L.S., Cass W.A. and Dwoskin L.P. Nicotinic receptor modulation
of dopamine transporter function in rat striatum and medial prefrontal cortex.
J. Pharmacol. Exp. Ther. 308: 367-377, 2004.
Harrod S.B., Dwoskin L.P. and Bardo M.T. Lobeline produces conditioned
taste avoidance in rats. Pharmacol. Biochem. Behav., 78:1-5, 2004.
Zheng G., Dwoskin L.P. and Crooks P.A. The preparation of 2arylmethylidene-8-methyl-8-azabicyclo[3.2.1]octan-3-ones. Synth.
Commun., 34: 1931-1942, 2004.
Dwoskin L.P., Sumithran S.P., Zhu J., Deaciuc A.G., Ayers J.T. and Crooks
P.A. Subtype-selective nicotinic receptor antagonists: potential as tobacco
use cessation agents. Bioorg. Med. Chem. Lett., 14:1863-1867, 2004.
Crooks P.A., Ayers J.T., Rui X., Sumithran S.P., Grinevich V.P., Wilkins
L.W., Deaciuc A.G., Allen D. and Dwoskin L.P. Development of subtype
selective nicotinic receptor ligands as receptor antagonists. Bioorg. Med.
Chem. Lett., 14:1869-1874, 2004.
Zheng G., Parkin S., Dwoskin L.P. and Crooks P.A. Two isomers of 2,4dibenzyl-8-azabicyclo[3.2.1]octan-3-ol. Acta Crystallogr. C. 60(Pt 1) o9-11,
2004.
Miller D.K., Crooks P.A., Zheng G., Grinevich V.P., Norrholm S.D. and
Dwoskin L.P. Lobeline analogs with enhanced affinity and selectivity for
plasmalemma and vesicular monoamine transporters and diminished affinity
Linda P. Dwoskin
Curriculum Vitae
Page 31
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
at 42* and 7* nicotinic receptors. J. Pharmacol. Exp. Ther. 310:10351045, 2004.
Zheng G., Dwoskin L.P. and Crooks P.A. Indirect trapping of the retroconjugate addition reaction intermediate involved in the epimerization of
lobeline: Application to the synthesis of (-)-sedamine. J. Org. Chem. 69:
8514-8517, 2004.
Neugebauer NM, Cunningham ST, Zhu J, Bryant RI, Middleton LS, &
Dwoskin L.P. Effects of environmental enrichment on behavior and
dopamine transporter function in medial prefrontal cortex in adult rats
prenatally treated with cocaine. Dev. Brain Res., 153:213-223, 2004.
Zheng G., Dwoskin L.P., Deaciuc A.G., Zhu J., Jones M.D., Crooks P.A.
Lobelane analogues as novel ligands for the vesicular monoamine
transporter-2. Bioorg. Med. Chem., 13:3899-3909, 2005.
Zhu J., Apparsundaram S., Bardo M.T., Dwoskin L.P. Environmental
enrichment decreases cell surface expression of the dopamine transporter
in rat medial prefrontal cortex. J. Neurochem., 93:1434-1443, 2005.
Geldenhuys W.J., Lockman P.R., Nguyen T.H., Van der Schyf C.J., Crooks
P.A., Dwoskin L.P. and Allen D.D. 3D-QSAR study of N-n-alkylnicotinium
analogs at the blood-brain barrier choline transporter. Bioorg. Med. Chem.
13:4253-4261, 2005.
Rauhut A.S., Dwoskin L.P. and Bardo M.T. Tolerance does not develop to
the decrease in nicotine self-administration produced by repeated bupropion
administration. Nicotine and Tobacco Res., 7:901-907, 2005.
Zheng G., Dwoskin L.P., Deaciuc A.G., Norrholm S.D. and Crooks P.A.
Defunctionalized lobeline analogues: Structure-activity of novel ligands for
the vesicular monoamine transporter. J. Med. Chem., 48:5551-5560, 2005.
Sumithran S.P., Crooks P.A., Xu R., Zhu J., Deaciuc A.C., Wilkins L.H. and
Dwoskin L.P. Incorporation of unsaturation into the N-n-alkyl chain of the
nicotinic receptor antagonists, NONI and NDNI: Effect on affinity and
selectivity. AAPS J, 7:E201-E217, 2005.
Papke R.L., Zheng G., Horenstein N.A., Dwoskin L.P. and Crooks P.A.
The characterization of a novel rigid nicotine analog with alpha7-selective
nicotinic receptor agonist activity and modulation of agonist properties by
boron inclusion. Bioorg. Med. Chem. Lett., 15:3874-3880, 2005.
Zheng G., Dwoskin L.P., Deaciuc A.G. and Crooks P.A. Synthesis and
evaluation of a series of tropane analogues as novel vesicular monoamine
transporter-2 ligands. Bioorg. Med. Chem. Lett. 15:4463-4466, 2005.
Ayers J.T., Sonar V.N., Parkin S., Dwoskin L.P. and Crooks P.A.
1R,2R,5R-(+)-2-hydroxypinan-3-one ketimine. Acta Cryst., E61, o2682o2684, 2005.
Ayers J.T., Clauset A., Schmitt J.D., Dwoskin L.P. and Crooks P.A.
Molecular modeling of mono- and bis-quaternary ammonium salts as
ligands at the 42* nicotinic acetylcholine receptor subtype using nonlinear techniques. AAPS J 7:E678-685, 2005.
Linda P. Dwoskin
Curriculum Vitae
Page 32
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
Huang X., Zheng F., Crooks P.A., Dwoskin L.P. and Zhan C.G. Modeling
multiple species of nicotine and deschloroepibatidine interacting with 42
nicotinic acetylcholine receptors: From microscopic binding to
phenomenological binding affinity. J. Am. Chem. Soc. 127:14401-14414,
2005.
Ayers J.T., Xu R., Dwoskin L.P. and Crooks P.A. A general procedure for
the enantioselective synthesis of the CNS-active minor tobacco alkaloids:
Nornicotine, anabasine and anatabine. AAPS J AAPS-NIDA Symposium,
Frontiers in Science: Drug Addiction: From Basic Research to Therapeutics,
AAPS Journal 7:E752-758, 2005.
Wei X., Sumithran S.P., Deaciuc A.G., Burton H., Bush L., Dwoskin L.P.
and Crooks P.A. Identification and synthesis of novel alkaloids from the root
system of Nicotinana tabacum: Affinity for neuronal nicotinic acetylcholine
receptors. Life Sci: Special Issue, National Institutes of Health (NIDA)
Symposium on: Naturceuticals and Nutraceuticals, 78:495-505, 2005.
Wilkins L.H., Miller D.K., Crooks P.A. and Dwoskin L.P. N-nAlkylnicotinium analogs, a novel class of antagonists at 42* nicotinic
acetylcholine receptors: Inhibition of S(-)-nicotine-evoked 86Rb+ efflux from
rat thalamic synaptosomes. AAPS Journal: AAPS-NIDA Symposium,
Frontiers in Science: Drug Addiction: From Basic Research to Therapeutics,
AAPS Journal 7:E922-930, 2006.
Zheng F., Bayram E., Ayers J.T., Dwoskin L.P., Zhan C.-G., Schmitt J.D.
and Crooks P.A. QSAR modeling of mono- and bis-quaternary ammonium
salts that act as antagonists at nicotinic receptor mediating dopamine
release. Bioorg. Med. Chem. 14:3017-3037, 2006.
Neugebauer, N. S., Zhang, Z., Crooks, P. A., Dwoskin, L. P. and Bardo, M.
T. Effect of a novel nicotinic receptor antagonist, N,N’-dodecane-1,12-diylbis-3-picolinium dibromide (bPiDDB), on nicotine self-administration and
hyperactivity in rats. Psychopharmacology 184:426-434, 2006.
Chen J., Deaciuc A.G., Dwoskin L.P., Bai D. and Crooks P.A. N,NDisubstituted piperazines and homopiperazines: Synthesis and affinities at
42* and 7* neuronal nicotinic acetylcholine receptors. J. Enz. Inhibit.
Med. Chem. 21:667-680, 2006.
Zheng G., Horton D., Deaciuc A.G., Dwoskin L.P., Crooks P.A. Des-keto
lobeline analogs with increased potency and selectivity at dopamine and
serotonin transporters. Bioorg. Med. Chem. Let, 16:5018-5021, 2006.
Wooter T.E., Dwoskin L.P. and Bardo M.T. Age and sex differences in the
locomotor effects of repeated methylphenidate in rats classified as high or
low responders. Psychopharmacology 188:18-27, 2006.
Zheng G., Dwoskin L.P. and Crooks P.A. Vesicular monoamine
transporter 2: Role as a novel target for drug development. AAPS Journal,
NIDA -AAPS Symposium on Drugs of Abuse: Mechanisms of Toxicity,
Toxicokinetics and Medical Consequences of Drugs of Abuse", 8(4), E682E692, 2006.
Linda P. Dwoskin
Curriculum Vitae
Page 33
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
Dwoskin L.P., Rauhut A.S., King-Pospisil K.A. and Bardo M.T. Review of
the pharmacology and clinical profile of bupropion, an antidepressant and
tobacco use cessation agent. CNS Drug Reviews, 12(3-4):178-207, 2006.
Huang X., Chen X., Zheng F., Crooks P.A., Dwoskin L.P. and Zhan C.-G.
Modeling subtype-selective agonists binding with α4ß2 and α7 nicotinic
acetylcholine receptors: Effects of local binding and lon-range electrostatic
interactions. J. Med. Chem. 49:7661-7674, 2006.
Middleton L.S., Crooks P.A., Wedlund P.J., Cass W.A. and Dwoskin L.P.
Nornicotine inhibition of dopamine transporter function in striatum via
nicotinic receptor activation. Synapse 61:157-165, 2007.
Middleton L.S., Apparsundaram S., King-Pospisil K.A. and Dwoskin L.P.
Nicotine increases dopamine transporter function in rat striatum through a
trafficking-independent mechanism. Eur J Pharmacol 554:128-136, 2007.
Bardo M.T., Williams Y., Dwoskin L.P., Moynahan S.E., Berry I.B. and
Martin C.A. The sensation seeking trait and substance use: Research
findings and clinical implications. Cur Psychiat Rev 3:3-13, 2007.
Stairs D.J., Neugebauer N., Wei X., Cassis L., Crooks P.A., Dwoskin L.P.
and Bardo M.T. In vivo pharmacology of nornicotine enantiomers: Effects
on intravenous S(-)-nicotine self-administration and cardiovascular function
in rats. Psychopharmacology, 190:145-155, 2007.
Rahman S., Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P. and
Bardo M.T. The effects of a novel nicotinic receptor antagonist, N,Ndodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and
repeated nicotine-induced increases in extracellular dopamine in rat nucleus
accumbens. Neuropharmacology, 52:755-763, 2007.
Zheng F., Zheng G., Deaciuc A.G., Zhan C.G., Dwoskin L.P. and Crooks
P.A. Computational neural network analysis of the affinity of lobeline and
tetrabenazine analogs for the vesicular monoamine transporter -2. Bioorg
Med Chem. 15:2975-2992, 2007.
Papke RL, Dwoskin LP and Crooks PA. The pharmacological fingerprint of
nAChRs subtypes utilizing nicotine and nornicotine: Relevance to nicotine
dependence and drug discovery. J. Neurochem. 101:160-167, 2007.
Neugebauer N.M., Harrod S.B., Stairs D.J., Crooks P.A., Dwoskin L.P. and
Bardo M.T. Lobelane decreases methamphetamine self-administration in
rats. Eur. J. Pharmacol. 571:33-38, 2007.
Zhu J, Bardo MT, Bruntz RC, Stairs DJ and Dwoskin LP. Individual
differences in response to novelty predict prefrontal cortex dopamine
transporter function and cell surface expression. Eur. J. Neurosci. 26:717728, 2007
Zhu J., Bardo M.T., Green T.A., Wedlund P.J. and Dwoskin L.P. Nicotine
increases dopamine clearance in medial prefrontal cortex in rats raised in
an enriched environment. J. Neurochem., Epub ahead of print, 2007.
Dwoskin L.P., Joyce B.M., Zheng G., Neugebauer N.M., Manda V.K.,
Lockman P., Papke R.L., Bardo M.T. and Crooks P.A. Discovery of a novel
nicotinic receptor antagonist for the treatment of nicotine addiction: 1(-3-
Linda P. Dwoskin
Curriculum Vitae
Page 34
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
Picolinium)-12-triethylammonium-dodcane dibromide (TMPD). Biochem
Pharmacol 74:1271-1282, 2007.
Norrholm S.D., Horton D.B. and Dwoskin L.P. The promiscuity of the
dopamine transporter: Implications for the kinetic analysis of [ 3H]serotonin
uptake in rat hippocampal and striatal synaptosomes. Neuropharmacology,
53:982-989, 2007.
Zheng G., Zhang Z., Pivarvarchyk M., Deaciuc A.G., Dwoskin L.P. and
Crooks P.A. bis-Azaaromatic quaternary ammonium salts as antagonists at
nicotinic receptors mediating nicotine-evoked dopamine release: An
investigation of binding conformation. Bioorg. Med. Chem. Let., 17:67346738, 2007.
Zheng G., Sumithran S.P., Deaciuc A.G., Dwoskin L.P. and Crooks P.A.
tris-Azaaromatic quaternary ammonium salts: Novel templates as
antagonists at nicotinic receptors mediating nicotine-evoked dopamine
release. Bioorg. Med. Chem. Let., 17:6701-6706, 2007.
Rahman S., Zhang Z., Papke R.L., Crooks P.A., Dwoskin L.P. and Bardo
M.T. Region-specific effects of the novel nicotinic receptor antagonist N,N’dodecane-1,12-diyl-bis-3-picolinium bromide (bPiDDB) on the nicotineinduced increase in extracellular dopamine: an in vivo reverse microdialysis
study. Br. J. Pharmacol., Epub ahead of print, 2007.
Lockman P.R., Manda V.K., Geldenhuys W.J., Mittapalli R.K., Thomas F.,
Albayati Z.F., Crooks P.A., Dwoskin L.P. and Allen D.D. Carrier-mediated
transport at of the quaternary ammonium neuronal nicotinic receptor
antagonist, N,N’-dodecyl-bis-picolinium dibromide (bPiDDB) at the bloodbrain barrier. J. Pharmacol. Exp. Ther., 324:244-250, 2008
Kantak K.M., Singh T., Kerstetter K.A., Dembro K.A., Mutebi M.M., Harvey
R.C., Deschepper C. F. and Dwoskin L.P. Advancing the spontaneous
hypertensive rat model of attention deficit hyperactivity disorder. Behav.
Neuroscience, in press, 2007.
Zheng F., Zheng G., Deaciuc A.G., Zhan C.G., Dwoskin L.P. and Crooks
P.A. Data mining on the affinity of N-n-alkyl nicotinium salts as antagonists
at α4ß2* nicotinic acetylcholine receptor (nAChR) subtype by computational
neural network analysis. J Enz Inhib Med Chem, in press, 2007
Sumithran S.P., Babu K.S., Ayers J.T.,, Deaciuc A.G., Zhu J., Crooks P.A.
and Dwoskin L.P. Novel N,N’-alkane-diyl-bis-3-picolinium analogs as
antagonists at nicotinic receptors: I. Inhibition of nicotine-evoked
neurochemical effects. J. Pharmacol. Exp. Ther., in review, 2008.
Wooters T.E., Papke R.L., Lockman P.R., Manda V.C., Mattapalli R.K.,
Allen D.D., Zhang Z., Crooks P.A., Dwoskin L.P. and Bardo M.T. Novel
N,N’-alkane-diyl-bis-3-picolinium analogs as antagonists at nicotinic
receptors: Brain bioavailability and inhibition of nicotine-induced behavioral
effects. J. Pharmacol. Exp. Ther., in review, 2008.
Papke R.L., Dwoskin L.P., Stokes C., Zheng G., Zhang Z., McIntosh J.M.
and Crooks P.A. A novel alpha6 nicotinic receptor chimera for the study of
nicotinic receptor antagonists. Mol. Pharmacol., in review, 2008.
Linda P. Dwoskin
Curriculum Vitae
Page 35
149.
150.
151.
152.
153.
154.
155.
Papke R.L., Crooks P.A., Lopez-Hernandez G., Zheng G., Sumithran S.P.
and Dwoskin L.P. tris-Azaaromatic quaternary ammonium salts: Nicotinic
receptor antagonist with selectivity for α7 subtype receptors. J. Pharmacol.
Exp. Ther., in review, 2007.
Wooters T.E., Dwoskin L.P. and Bardo M.T. Role of NMDA, AMPA and
mGluR5 glutamate receptors in the discriminative stimulus effects of
methamphetamine in rats. Psychopharmacology, in review, 2007.
Middleton L.S., Wedlund P. and Dwoskin L.P. Tolerance develops to the
nicotine enhancement of dopamine clearance in striatum and medial
prefrontal cortex. Neuroscience, in review, 2007.
Zhu J., Bardo M.T. and Dwoskin L.P. Environmental enrichment
differentially alters nicotine-induced enhancement of dopamine clearance in
rat nucleus accumbens shell and core. Neuropharmacology, in review,
2008.
Haubner A.J., Fu M.C., Ring J.R., Kennard E.J., Littleton J.M., Dwoskin
L.P. and Crooks P.A. Development of guanylated nicotine analogs: ligands
for the α4β2* and α7* neuronal nicotinic acetylcholine receptor subtypes.
Bioorg. Med. Chem. Let., in review, 2007.
Miller D.K., Harrod S.B., Green T.A., Bardo M.T. and Dwoskin L.P.
Lobeline attenuates the locomotor-activating properties of repeated
methamphetamine and repeated cocaine administration in rats. Pharmacol.
Biochem. Behav., in review, 2007.
Miller D.K., Zheng G., Sumithran S.P., Dhawan G.K., Crooks P.A. and
Dwoskin L.P. Structure activity studies on lobeline analogs: Mesotransdience potently inhibits nicotinic receptors mediating nicotine-evoked
[3H]dopamine and [3H]norepinephrine release. J. Pharmacol. Exp. Ther., in
review, 2007.
G. Patents
1.
“Nicotinic Receptor Antagonists in the Treatment of Neuropharmacological
Disorders”. By Peter A. Crooks, Linda P. Dwoskin and Alain Ravard, U.S.
Patent No. 5,691,365, November 25, 1997 (Licensed).
2.
"Nornicotine Enantiomers as a Treatment for Dopamine-Related Conditions
and Disease States". By Peter A Crooks, Linda P. Dwoskin and Michael T.
Bardo, U.S. Patent 5,776,957, July 8, 1998.
3.
“Lobeline Compounds as a Treatment for Psychostimulant Abuse and
Withdrawal, and Eating Disorders”. By Peter A. Crooks and Linda P.
Dwoskin U.S. Patent 5,830, 904, November 3, 1998 (Licensed).
4.
“Use of Lobeline Compounds in the Treatment for Central Nervous System
Diseases and Pathologies”. By Peter A. Crooks and Linda P. Dwoskin,
U.S. Patent 6,087,376, July 11, 2000.
5.
“Compounds Useful for the Treatment of CNS Pathologies”. By Peter A.
Crooks, Linda P. Dwoskin, Rui Xu and Vladimir Grinevich, (Docket No.
50229-193), U.S. Patent Application No. 60/228,766, August 30th, 2000.
6.
“Boron-Containing Nicotine Analogs for Use in the Treatment of CNS
Pathologies”. By Peter a Crooks, Linda P. Dwoskin, Rui Xu, Vladimir
Linda P. Dwoskin
Curriculum Vitae
Page 36
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Grinevich and Roger L. Papke, (Docket No. 50229-249), U.S. Patent
Application No. 60/261,822, May, 2001.
“Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant
Abuse and Withdrawal, Eating Disorders, and Central Nervous System
Diseases and Pathologies”. By Linda P. Dwoskin, Peter A. Crooks and
Marlon D. Jones, International Patent No. WO 108,678A1, February 8,
2001.
“Bridged Nicotine Compounds For Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Rui Xui and Vladimir
Grinevich, International Patent No. WO 02/17922, March 7, 2002.
“Chain-Modified Pyridino-N-Substituted Nicotine Compounds for Use In
the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P.
Dwoskin, Rui Xu and Joshua Ayers. Provisional U.S. Patent No. US
60/342,120, filed December 26th, 2001.
“Aza-aminotetralin Compounds for Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin and Rui Xu, submitted
to the Office of Intellectual Properties, University of Kentucky, July 8, 2001
(UK Case No. 1069, Docket No. 50229-281).
“bis-Pyridino Containing Compounds for Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin and Joshua Ayers,
submitted to the Office of Intellectual Properties, University of Kentucky,
November 12th, 2001 (UK Case No. 1101).
“Cis-2,6-Disubstituted Piperidines as Modulators of Nicotinic Acetylcholine
Receptor Mediated Neurotransmitter Release, Uptake and Storage:. By
Peter A. Crooks, Guangrong Zheng, Dennis K. Miller, Seth Norrholm,
Vladimir P. Grinevich and Linda P. Dwoskin, U.S. Patent Application No.
US 10/163,633, June 7th, 2002.
“Boron-Containing Nicotine Analogs for Usein the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Vladimir P. Grinevich
and Rui Xu, International Patent No. WO 02/057275, July 25 th, 2002.
“Cis-2,6-disubsituted Piperidines for the Treatment of Psychostimulant
Abuse and Withdrawl, Eating Disorders, and Central Nervous System
Diseases and Pathologies”. By Linda P. Dwoskin, Peter A. Crooks and
Marlon D. Jones, U.S. Patent No. 6,455,543, September 24 th, 2002.
“Bridged Nicotine Compounds For Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Rui Xu and Vladimir
P. Grinevich, U.S. Patent Application No. 09/941,926, filed August 30, 2001,
Publication No. US 2002/0099069 A1, Publication Date, July 25th, 2002.
“Bridged Nicotine Compounds for Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Rui Xu and Vladimir
P. Grinevich, Australian Patent No. AU 8,687,501, July 25 th, 2002.
“Cis-2,6-disubstituted Piperidines for the Treatment of Psychostimulant
Abuse and Withdrawal, Eating Disorders, and Central Nervous System
Diseases and Pathologies". By Linda P. Dwoskin, Peter A. Crooks and
Marlon D. Jonesm Aystralian Patent No. AU 6,386,700, September 24 th,
2002.
Linda P. Dwoskin
Curriculum Vitae
Page 37
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
“Boron-containing Nicotine Analogs for use I the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Vladimir P. Grinevich
and Rui Xu, Australian Patent Application No. AU 2002214900, January
17th, 2002.
“Bridged Nicotine Compounds for Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Rui Xu and Vladimir
P. Grinevich, U.S. Patent No. 6,503,922, January 7 th, 2003.
“Chain-Modified Pyridino-N-Substituted Nictine Compounds for Use In the
Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P. Dwoskin,
Rui Xu and Joshua Ayers, U.S. Patent Application No. 10/328,192, filed
December 26th, 2002.
“Cis-2,6-disubstituted Pieridines for the Treatment of Psychostimulant
Abuse and Withdrawal, Eating Disorders, and Central Nervous System
Diseases and Pathologies”. By Linda P. Dwoskin, Peter A. Crooks and
Marlon D. Jones, U.S. Patent Application, Publication No. US
2003/0100547 A1, Publication Date May 29th, 2003.
“Chain-Modified Pyridino-N-Substituted Nicotine compounds for Use In
the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P.
Dwoskin, Rui Xu and Joshua Ayers, U.S. Patent Application No. US
2003/0225142A1, December 4th, 2003.
“2,6-Disubstitued Piperidines as Modulators of Nicotinic Acetylcholine
Receptor Mediated Neurotransmitter Release, Uptake and Storage”. By
Peter A. Crooks, Linda P. Dwoskin, Dennis K. Miller, Vladimir P.
Grinevich, Seth D. Norrholm and Guangrong Zheng, U.S. Patent
Application No. US 2004/0019081 A1, January 29th, 2004.
“2,6-Disubstitued Piperidines as Modulators of Nicotinic Acetylcholine
Receptor Mediated Neurotransmitter Release, Uptake and Storage”. By
Peter A. Crooks, Linda P. Dwoskin, Dennis K. Miller, Vladimir P.
Grinevich, Seth D. Norrholm and Guangrong Zheng, U.S. Patent No. US
6,703,406, March 9th, 2004.
“Disubstituted Piperidine and Piperazine Compounds”. By Peter A.
Crooks, Linda P. Dwoskin, Guangrong Zheng, Marlon Jones, Dennis K.
Miller, Seth Norrholm and Sairam Krishnamurthy (Docket No. 64684024), U.S. Patent Application, filed April 1st, 2004.
“2,6-Disubstituted Piperidines as Modulators of Nicotinic Acetylcholine
Receptor Mediated Neurotransmitter Release, Uptake and Storage”. By
Peter A. Crooks, Linda P. Dwoskin, Dennis K. Miller, Vladimir P.
Grinevich, Seth D. Norrholm and Guangrong Zheng, U.S. Patent
Application No. US 2004/006098, January 29th, 2004.
“bis-Pyridino-containing Compounds for Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Joshua T. Ayers
and Vladimir Grinevich, Provisional U.S. Patent Application No.
60/533,213, December 31st, 2003.
“2,6-Disubstituted Piperidines and Pierazine Compounds”. By Peter A.
Crooks, Linda P. Dwoskin, Marlon D. Jones, Dennis K. Miller, Seth D.
Linda P. Dwoskin
Curriculum Vitae
Page 38
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Norholm, Guangrong Zheng and Sairam Krishamurthy, U.S. Patent
Application No. 10/813,647, March 31st, 2004.
“Cis-2,6-disubstitued Piperidines for the Treatment of Psychostimulant
Abuse and Withdrawal, Eating Disorders, and Central Nervous System
Diseases and Pathologies”. By Linda P. Dwoskin, Peter A. Crooks and
Marlon D. Jones, U.S. Patent Application No. 10/231,156, August 30th,
2002.
“2,6-Disubstitued Piperidines and Piperazine Compounds”. By Peter A.
Crooks, Linda P. Dwoskin, Guangrong Zheng, Dennis K. Miller, Seth D.
Norholm, Krishnan Sairam and Marlon D. Jones, U.S. Patent No.
US2004/266824, December 30th, 2004.
“bis-Pyridino-containing Compounds for Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Joshua T. Ayers
and Vladimir Grinevich, U.S. Patent Application No. 11/027,675, January
3rd, 2005.
“2,6-Disubstitued Piperidines for the Treatment of Psychostimulant Abuse
and Withdrawal, Eating Disorders, and Central Nervous System Diseases
and Pathologies”. By Peter A. Crooks, Linda P. Dwoskin and Marlon D.
Jones, U.S. European Patent No. EP1513513, Martch 16th, 2005.
“bis-Pyridino-containing Compounds for Use in the Treatment of CNS
Pathologies”. By Peter A. Crooks, Linda P. Dwoskin, Joshua T. Ayers,
Vladimir Grinevich and Sangeetha P. Sumithran, International Patent No.
WO 2005066129 A2, July 27th, 2005.
“Cis-2,6-disubstitued Piperidines for the Treatment of Psychostimulant
Abuse and Withdrawal, Eating Disorders, and Central Nervous System
Diseases and Pathologies”. By Linda P. Dwoskin, Peter A. Crooks and
Marlon D. Jones, U.S. Patent No. US 6,943,177, September 13 th, 2005.
“R(+)- and S(-)-Nornicotine for the Treatment of Pain”. By Joseph R.
Holtman, Peter A. Crooks and Linda P. Dwoskin, U.S. Patent
Application, submitted to the University of Kentucky Intellectual Properties
Committee, November 17th, 2005. Case No. 1377.
“Novel tris-Quaternary Ammonium Salts that Interact with Neuronal
Nicotinic Receptors”. By Peter A. Crooks, Guangrong Zheng, Linda P.
Dwoskin, Roger Papke and Sangeetha P. Sumithran, U.S. Patent
Application, US 60/753,970, December 12th, 2005.
“bis-Quaternary Ammonium Compounds that Interact with Neuronal
Nicotinic Receptros”. By Peter A. Crooks, Guangrong Zheng, Linda P.
Dwoskin and Sangeetha P. Sumithran, UK Case No. 1401; U.S. Patent
Application, US 60/758,622, January 13th, 2006.
“mono-Quaternary Ammonium Compounds that Interact with Neuronal
Nicotinic Receptors”. By Peter A. Crooks, Guangrong Zheng, Zhenfa
Zhang, Linda P. Dwoskin and Sangeetha P. Sumithran, U.S. Patent
Application, US 60/814,423, July 14th, 2006.
“bis-Quaternary Ammonium Cyclophane Compounds that Interact with
Neuronal Nictinic Receptors”. By Peter A. Crooks, Linda P. Dwoskin,
Guangrong Zheng, Zhenfa Zhang, Sangeetha P. Sumithran, David D.
Linda P. Dwoskin
Curriculum Vitae
Page 39
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Allen and Paul Lockman, UK Case No. 1429, U.S. Provisional Patent
Application, US 60/799811, May 12th, 2006.
“bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal
Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong
Zheng, Zhenfa Zhang, Linda P. Dwoskin, Sangeetha P. Sumithran and
Marharyta Pivavarchyk, UK Case NO. 1439; U.S. Provisional Patent
Application 60/814640, May 31st, 2007.
“Chain-Modified Pyridino-N-Substituted Nicotine Compounds for Use in
the Treatment of CNS Pathologies”. By Peter A. Crooks, Linda P.
Dwoskin, Rui Xu and Joshua T. Ayers, U.S. Patent No. US 7,091,357
B2, August 15th, 2006.
“tetrakis-Quaternary Ammonium Compounds that Interact with neuronal
Nicotinic Receptors”. By Peter A. Crooks, Linda P. Dwoskin, Zhenfa
Zheng and Marharyta Pivavarchyk, submitted to the University of
Kentucky Intellectual Properties Office, Case No. 1494, April, 2007.
“bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal
Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong
Zheng, Linda P. Dwoskin and Sangeetha P. Sumithran, UK Case No.
1401; filed as a U.S. Utility Patent Application January 12th, 2007.
“bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal
Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong
Zheng, Linda P. Dwoskin, Sangeetha P. Sumithran and Marharyta
Pivavarchyk, UK Case No. 1439; filed as a U.S. Utility Patent Application
May 31, 2007.
“bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal
Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P.
Dwoskin, Guangrong Zheng, Zhenfa Zhang, Sangeetha P. Sumithran
David D. Allen and Paul Lockman, UK Case No. 1429, Filed as a U.S.
Utility Patent Application, May 12th, 2007.
“tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal
Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Guangrong
Zheng, Linda P. Dwoskin, Roger Papke and Sangeetha P. Sumithran,
International Patent No. WO 2007076112 A2, July 5th, 2007.
“bis-Quaternary Ammonium Salts and methods for Modulating Neuronal
Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda P.
Dwoskin, Guangrong Zheng and Sangeetha P. Sumithran , International
Patent No. WO 2007/094912, August 23rd, 2007.
“bis-Quaternary Ammonium Cyclophane Compounds that Interact with
Neuronal Nicotinic Acetylcholine Receptors”. By Peter A. Crooks, Linda
P. Dwoskin, Guangrong Zheng, Zhenfa Zhang, Sangeetha P. Sumithran,
David D. Allen and Paul Lockman, UK Case No. 1429, International
Patent No. WO 2007/133614, November 22nd, 2007.
“Use of Lobeline Daisasteromers in the Treatment of Central Nervous
System Diseases, Pathologies, and Drug Abuse”. By Peter A. Crooks,
Linda P. Dwoskin and David R. Worthern, U.S. Provisional Application
No. 60/985,189, November 2nd, 2007.
Linda P. Dwoskin
Curriculum Vitae
Page 40
H. Book Chapters
1.
Zahniser N.R., Peris J. and Dwoskin L.P. Modulation of neurotransmitter
release: An assay for receptor function. In: Chemical and Functional
Assays of Receptor Binding, Society for Neuroscience: Washington, D.C.,
p. 73-81, 1986.
2.
Dwoskin L.P., Neal B.S. and Sparber S.B. A behavior assay for receptor
action(s) of drugs. In: Advances in Behavioral Pharmacology, Vol 6, T.
Thompson and P.B. Dews (Eds), New York: Lawrence Erlbaum Associates,
Inc., p. 45-61, 1987.
3.
Dwoskin L.P., Gerhardt G.A., Drebing C.J., Wilcox C.C. and Zahniser N.R.
Uptake and release of dopamine from rat striatal slices: Comparison of
PCP, amphetamine and nomifensine. In: Pharmacology and Functional
Regulation of Dopaminergic Neurons, P.M. Beart, G. Woodruff and D.M.
Jackson (Eds.), Macmillan, p. 248-250, 1988.
4.
Zahniser N.R., Peris J.P., Curella P., Dwoskin L.P., O'Keefe L. and Boyson
S.J. Repeated cocaine administration results in supersensitive nigrostriatal
D-2 dopamine autoreceptors. In: Pharmacology and Functional Regulation
of Dopaminergic Neurons, P.M. Beart, G. Woodruff and D.M. Jackson
(Eds.), Macmillan, p. 168-174, 1988.
5.
Zahniser N.R., Peris P., Dwoskin L.P., Curella P., Yasuda R.P., O'Keefe L.
and Boyson S.J. Sensitization to cocaine in the nigrostriatal dopamine
system. In: Technical Review Meeting on the Mechanisms of Cocaine
Abuse and Toxicity, National Institute on Drug Abuse Research Monograph,
Washington, D.C., p. 55-77, 1988.
6.
Dwoskin L.P. and Carney J.M. Genetic isolation of in vivo and in vitro PCP
responsiveness. In: Multiple Sigma and PCP Receptor Ligands:
Mechanisms for Neuromodulation and Protection, E.F. Domino and J.M.
Kamenka (Eds.) NPP Books, Ann Arbor, MI, pp. 859-878, 1992.
7.
Carney J.M., Seale T.W., Bardo M.J. and Dwoskin L.P. Qualitative and
quantitative differences in the behavioral effects of phencyclidine in inbred
mice. In: Multiple Sigma and PCP Receptor Ligands: Mechanisms for
Neuromodulation and Protection, E.F. Domino and J.M. Kamenka (Eds.)
NPP Books, Ann Arbor, MI, pp. 607-618, 1992.
8.
Bardo M.J. and Dwoskin L.P. Biological connection between drug and
novelty seeking motivational systems. In: 50th Annual Nebraska
Symposium on Motivation, Editors, Bevans R.A. and Bardo M.T., Nebraska
University Press, Lincoln, NE, pp.127-158, 2004.
9.
Garrett B.E., Dwoskin L.P. Bardo M.T., and Henningfield J. Behavioral
Pharmacology of Nicotine Reinforcement, In: Tobacco: Tobacco: Science,
policy and public health” eds. Peter Boyle, Nigel Gray, Jack Henningfield,
John Seffrin and Witold Zatonski, Oxford University Press, New York, NY
pp. 149-165, 2004.
10.
Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang
Z, Bardo MT and Crooks PA. Targeting reward-relevant nicotinic receptors
in the discovery of novel pharmacotherapeutic agents to treat tobacco
Linda P. Dwoskin
Curriculum Vitae
Page 41
dependence. 55th Annual Nebraska Symposium on Motivation: The
Motivational Impact of Nicotine and its Role in Tobacco Use. Eds RA
Bevins and AR Caggiula, Springer, in press.
I. Abstracts
1.
Dwoskin L.P., Tilson H.A., Kantak K.M., Stein J.M. and Wayner M.J.
Effects of imipramine and mescaline on the in vivo metabolism of 3H-Ltryptophan in the cerebrolateral ventricles of rats. Soc. Neurosci. Abstr. 2:
847, 1976.
2.
Dwoskin L.P., Sprague G.L., Takemori A.E. and Sparber S.B. Differential
displacement of 3H-morphine by naloxone in vivo between naive and
morphine-withdrawn rats. The Pharmacologist, 20: 168, 1978.
3.
Dwoskin L.P. and Sparber S.B. Yohimbine antagonizes clonidine-induced
behavioral suppression. The Pharmacologist, 22: 294, 1980.
4.
Dwoskin L.P. and Sparber S.B. A comparison of yohimbine, mianserin and
chlorpromazine as antagonists of clonidine's effect on fixed ratio behavior in
rats. IUPHAR Tokyo, Japan, Eighth International Congress of
Pharmacology, 619P, 1981.
5.
Neal B.S., Dwoskin L.P. and Sparber S.B. Yohimbine has partial antidopaminergic and lysergic acid diethylamide antagonistic activity only at
nonselective, behaviorally active doses. Soc. Neurosci. Abstr. 8: 396,
1982.
6.
Kleven M.S., Dwoskin L.P. and Sparber S.B. Lysergic acid diethylamide
(LSD) attenuates 5-hydroxytryptophan (5-HTP) induced increases in 5hydroxyindoleacetic acid (5-HIAA) in ventricular perfusate collected during
operant behavior. Federation Proceedings, 1983.
7.
Dwoskin L.P. and Sparber S.B. A comparison of mianserin and
methysergide as antagonists of the effect of lysergic acid diethylamide on
fixed ratio behavior in rats. Soc. Neurosci. Abstr. 9: 125, 1983.
8.
Dwoskin L.P., Stack J., Allen R.G. and Kendall J.W. Low concentrations of
ascorbate inhibit the secretion of pro-opiomelanocortin (POMC) derived
peptides from anterior and intermediate lobes of mouse pituitary. Soc.
Neurosci. Abstr. 10: 85, 1984.
9.
Dwoskin L.P. and Zahniser N.R. Robust Modulation of 3H-dopamine
release from rat striatal slices by D-2 dopamine receptors. Soc. Neurosci.
Abstr. 11: 712, 1985.
10.
Zahniser N.R. and Dwoskin L.P. Depletion of endogenous dopamine can
enhance the inhibition of stimulation-evoked release of 3H-dopamine from
rat striatal slices by D-2 dopamine receptor agonists. Soc. Neurosci. Abstr.
11: 713, 1985.
11.
Dwoskin L.P., Gerhardt G.A. and Zahniser N.R. Effect of alphamethyltyrosine treatment on stimulation-evoked endogenous dopamine release
from rat striatal slices. Soc. Neurosci. Abstr. 12: 805, 1986.
Linda P. Dwoskin
Curriculum Vitae
Page 42
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Peris J., Dwoskin L.P. and Zahniser N.R. Biphasic modulation of (3H)Dapartate release by D-2 dopamine receptors in rat striatal slices. Soc.
Neurosci. Abstr. 12: 489, 1986.
Zahniser N.R., Yasuda R.P., Dwoskin L.P., Philpott K. and Dunwiddie T.V.
Repeated cocaine administration: Comparison between central dopaminergic and noradrenergic systems. Soc. Neurosci. Abstr. 12: 142, 1986.
Dwoskin L.P., Gerhardt G.A., Wilcox C.C. and Zahniser N.R. Uptake and
release of dopamine from rat striatal slices: Effects of nomifensine, cocaine
and PCP. IUPHAR Sydney, Australia, Xth International Congress of
Pharmacology, 1987.
Dwoskin L.P., Gerhardt G.A., Drebing C.J., Wilcox C.C. and Zahniser N.R.
Uptake and release of dopamine from rat striatal slices: Comparison of
PCP, amphetamine and nomifensine. Dopamine 87, Satellite Symposium,
Hunter Valley, Australia, 1987.
Zahniser N.R., Dwoskin L.P., Peris J., Yasuda R.P. and Philpott K.
Repeated cocaine administration results in supersensitive striatal D-2
dopamine autoreceptors. Dopamine 87, Satellite Symposium, Hunter
Valley, Australia, 1987.
Dwoskin L.P., Gerhardt G.A., Drebing C.J., Jacobson A.E., Lessor R.A.,
Rice K.C. and Zahniser N.R. Uptake and release of endogenous dopamine
from rat striatal slices: Interaction of metaphit with PCP and nomifensine.
Soc. Neurosci. Abstr. 13: 1109, 1987.
Wilcox C.C., Dwoskin L.P., Gerhardt C.J. and Zahniser N.R. Comparison
of the effects of PCP, cocaine, amphetamine and nomifensine on
electrically- evoked endogenous dopamine release and re-uptake from rat
striatal slices. Soc. Neurosci. Abstr. 13: 1109, 1987.
Zahniser N.R., Peris J., Curella P. and Dwoskin L.P. Delayed increase in
amphetamine-induced release of dopamine from striatum following repeated
cocaine administration. Soc. Neurosci. Abstr. 14: 659, 1988.
Dwoskin L.P. Neurotensin evokes the production of endogenous
dihydroxyphenylacetic acid (DOPAC) from superfused rat striatal slices.
Soc. Neurosci. Abstr. 14: 114, 1988.
Dwoskin L.P. and Buxton S.T. Neurotensin-evoked overflow of
endogenous dihydroxyphenylacetic acid from superfused rat striatal slices is
greatly diminished by stress. Soc. Neurosci. Abstr. 15: 582, 1989.
Buxton S.T., Gerhardt G.A., Zahniser N.R., Jacobson A.E., Lessor R.A. and
Dwoskin L.P. Metaphit antagonizes the effect of PCP and nomifensine, not
amphetamine, on endogenous dopamine release in rat striatal slices. Soc.
Neurosci. Abstr. 15: 108, 1989.
Finn I.B., Dwoskin L.P., Seale T.W. and Carney J.M. Correlation of
phencyclidine (PCP)-induced stimulation of locomotor activity with release
of endogenous dopamine in vitro in two inbred mouse strains. Soc.
Neurosci. Abstr. 15: 1225, 1989.
Dwoskin L.P., Leibee L.L., Buxton S.T. and Carney J.M. PCP-induced
dopamine release in vitro: Tachyphylaxis and recovery of response. Soc.
Neurosci. Abstr. 16:1350, 1990.
Linda P. Dwoskin
Curriculum Vitae
Page 43
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Jewell-Smith A., Buxton S.T. and Dwoskin L.P. Irreversible inhibition of
dopamine uptake: A novel treatment for Parkinson's Disease. Soc.
Neurosci. Abstr. 16:1110, 1990.
Dwoskin L.P. and Carney J.M. PCP-induced dopamine release in vitro:
Tachyphylaxis and recover of response. Dopamine '90 Satellite Meeting of
the XIth International Congress of Pharmacology, 1990.
Jewell A., Painter D.J., Buxton S.T., Cassis L.A. and Dwoskin L.P. DuP
753, a nonpeptide angiotensin II-1 receptor antagonist, modulates
dopamine function in rat striatum. FASEB Journal 5:A864, 1991.
Jewell A.L., Buxton S.T., Leibee L.L., Cassis L.A. and Dwoskin L.P.
Angiotensin II increases dopamine release from rat striatal slices in vitro.
Soc. Neurosci. Abstr. 17:987, 1991.
Leibee L.L., Crooks P.A., Buxton S.T., Jewell A.L. and Dwoskin L.P.
Nicotine metabolites alter dopamine uptake and release in rat striatum in
vitro. Soc. Neurosci. Abstr. 17:1076, 1991.
Dwoskin L.P. and Carney J.M. Genetic isolation of in vivo and in vitro PCP
responsiveness. Third French-U.S. Seminar, Multiple Sigma and PCP
Receptor Ligands, pp. 52, 1992.
Carney J.M., Seale T.W. and Dwoskin L.P. Qualitative and quantitative
differences in the behavioral effects of phencyclidine and related
compounds using inbred mice. Third French-U.S. Seminar, Multiple Sigma
and PCP Receptor Ligands, pp. 104, 1992.
Jewell A.L., Wedlund P.J. and Dwoskin L.P. Sigma binding in brain and
liver from rats deficient in Cytochrome P450-2D1. Soc. Neurosci. Abst.
18:455, 1992.
Bowling S.L., Rowlett J.K., Bradley M., Dwoskin L.P. and Bardo M.T.
Environmental enrichment alters the behavioral response to amphetamines
but not to electrically-evoked dopamine release. Soc. Neurosci. Abst.
18:887, 1992.
Dwoskin L., Buxton S., Painter D., Jewell A., Hayden R. and Cassis L.
Chronic losartan administration modulates dopamine/angiotensin
interactions in rat striatum. The Pharmacologist 34(3):157, 1992.
Samant U., Painter D., Howard G., Dwoskin L. and Cassis L. Extrarenal
renin in central and peripheral renin-angiotensin systems. The FASEB J.
7(3): A220, 1273, 1993.
Dwoskin L.P., Buxton S.T., L.H. Teng and P.A. Crooks. Nornicotineinduced dopamine (DA) release from rat striatal slices is concentrationdependent, calcium-dependent and stereoselective. College on Problems
of Drug Dependence 55:11, 1993.
Jewell A.L., Carney J.M. and Dwoskin L.P. Inherent differences in brain
regional content of dopamine and serotonin in two inbred mouse strains.
College on Problems of Drug Dependence 55:11, 1993.
Dwoskin L.P., Teng L.H., Buxton S.T. and Crooks P.A. Is the
stereoselectivity of nicotine-induced dopamine (DA) release dependent
upon the presynaptic DA pool accessed? Gordon Conference on
Catecholamines, 1993.
Linda P. Dwoskin
Curriculum Vitae
Page 44
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
Dwoskin L.P., Jewell A.J., Buxton S.T., Bradley M. and Bardo M.T.
Environmental enrichment decreases the sensitivity of dopamine
autoreceptors in rat nucleus accumbens. Soc. Neurosci. Abstr. 19:822,
1993.
Teng L.H., Buxton S.T., Crooks P.A. and Dwoskin L.P. Stereoselectivity of
nicotine to induce dopamine (DA) release from superfused rat striatal slices:
Dependence upon prior DA loading. Soc. Neurosci. Abstr. 19:932, 1993.
Jewell A.L., Carney J.M. and Dwoskin L.P. PCP-induced DA release is
positively correlated with [3H]TCP, but not [3H]GBR 12935 binding, in
striatum from two inbred mice strains. Soc. Neurosci. Abstr. 19:1458, 1993.
Crooks P.A., Ravard A., Deo N., Teng L.H. and Dwoskin L.P. Nornicotine
and other minor tobacco alkaloids release [3H]dopamine from superfused
rat striatal slices. American Association Pharmaceutical Scientists Abstr.
10(10):S120, 1993.
Dwoskin L.P., Teng L.H., Buxton S.T. and Crooks P.A. Lobeline robustly
increases [3H]dopamine release from rat striatal slices. College on
Problems of Drug Dependence, 56:36, 1994.
Dwoskin L.P., Crooks P.A., Bradley M. and Bardo M.T. Locomotor and
motivational effects of S(–)nornicotine, a nicotine metabolite and minor
constituent of tobacco. XIIth International Congress of Pharmacology, pp.
363, 1994.
Dwoskin L.P., Teng L.H. and Crooks P.A. Lobeline evokes a marked
utilization of dopamine in rat striatum. International Symposium on Nicotine:
The Effects of Nicotine on Biological Systems II. Satellite Symposium of the
XIIth International Congress of Pharmacology, pp. 64, 1994.
Crooks P.A., Li M. and Dwoskin L.P. Detection of a long-lived nicotine
metabolite in rat brain following peripheral nicotine administration.
International Symposium on Nicotine: The Effects of Nicotine on Biological
Systems II. Satellite Symposium of the XIIth International Congress of
Pharmacology, pp. 126, 1994.
Teng L.H., Ravard A., Buxton S.T., Crooks P.A. and Dwoskin L.P.
N_Substituted nicotine analogs, a new class of nicotinic receptor antagonist.
International Symposium on Nicotine: The Effects of Nicotine on Biological
Systems II. Satellite Symposium of the XIIth International Congress of
Pharmacology, pp. 19, 1994.
Teng L.H., Buxton S.T., Crooks P.A. and Dwoskin L.P. The toxicity of
lobeline on central dopamine (DA) neurons in the rat. Society of Toxicology,
15:147, 1995.
Bevins A.R., Klebaur J.E., Dwoskin L.P. and Bardo M.T. Factors affecting
generalization between amphetamine and nicotine discriminative stimulus
effects. Assoc. for Behavioral Analysis, 21:121, 1995.
Dwoskin L.P. Does nornicotine, the active metabolite of nicotine and minor
tobacco alkaloid contribute to the abuse liability of tobacco smoking?
Gordon Research Conference on Catecholamines, 1995.
Dwoskin L.P., Teng L.H., Ravard A., Crooks P.A., Bradley M.C. and Bardo
M.T. Nornicotine, the active metabolite of nicotine, contributes to the abuse
Linda P. Dwoskin
Curriculum Vitae
Page 45
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
liability of tobacco smoking. Society for Research on Nicotine and Tobacco,
1:P06, 1995.
Crooks P.A., Li M. and Dwoskin L.P. Nornicotine, an active metabolite of
nicotine, is detected in brain following peripheral administration of
S(-)nicotine. Society for Research on Nicotine and Tobacco, 1:P07, 1995.
Dwoskin L.P., Wilkins L.H., Crooks P.A., Bradley M.C. and Bardo M.T.
Behavioral sensitization to nornicotine: Lack of correlation with [3H]nicotine
binding in rat whole brain. College on Problems of Drug Dependence,
57:143, 1995.
Crooks P.A, Wilkins L.H., Teng L.H., Ravard A. and Dwoskin L.P.
Neurochemical characterization of a new class of novel nicotinic receptor
antagonist. College on Problems on Drug Dependence, 57:137, 1995.
Dwoskin L.P., Teng L.H., Buxton S.T. and Crooks P.A. Nornicotine-evoked
[3H]dopamine release from rat striatal slices: Desensitization of the
response to nornicotine after prior exposure to nicotine. Soc. Neurosci.
Abstr. 21:1331, 1995.
Crooks P.A., Teng L.H., Ravard A., Buxton S.T., Cohen B.N., Allen D.D.
and Dwoskin, L.P. Development of a novel class of nicotinic receptor
antagonists: Inhibition of nicotine-evoked striatal dopamine release and the
electrophysiological response of a cloned nicotinic receptor subtype in
Xenopus oocytes. Soc. Neurosci. Abstr. 21:1834, 1995.
Teng L.H., Buxton S.T., Crooks P.A. and Dwoskin L.P. Evidence that
nornicotine acts to release dopamine from rat striatal slices by a nicotinic
receptor-mediated mechanism. Soc. Neurosci. Abstr. 21:1331, 1995.
Wilkins L.H., Crooks P.A., Ravard A., Yokel R.A. and Dwoskin L.P.
Development of a novel class of nicotinic receptor antagonists:
Displacement of [3H]nicotine binding from rat striatal membranes. Soc.
Neurosci. Abstr. 21:1834, 1995.
Valone J.M., Williamson A.P., Bevins R.A., Shaw W.B., Dwoskin L.P. and
Bardo M.T. The effects of differential rearing on the psychostimulant effect
of amphetamine and the dopamine transporter. Soc. Neurosci. Abstr.
21:1466, 1995.
Dwoskin L.P., Damaj M.I., Allen D.D., Wilkins L.H. and Crooks P.A.
Further characterization of a novel class of nicotinic receptor antagonists.
College on Problems of Drug Dependence, 58:37, 1996.
Crooks P.A., Teng L-H., Li M., Bardo M.T. and Dwoskin L.P. Cotinine
pharmacology: Brain uptake and metabolism, effects of dopamine release
and lack of behavioral sensitization after chronic administration to rats.
College on Problems of Drug Dependence, 58:29, 1996.
Dwoskin L.P., Moore S.E., Shaw W. and Butterfield D.A.
Methanethiosulfonate (MTS) inhibits dopamine (DA) transporter function in
rat striatum. Soc. Neurosci. Abstr. 22:323, 1996.
Teng L.H., Crooks P.A., Sonsalla P.K. and Dwoskin L.P. Lobeline potently
inhibits [3H]dopamine ([3H]DA) uptake into rat striatal vesicles and
synaptosomes, and promotes [3H]DA release from striatal vesicles and
slices. Soc. Neurosci. Abstr. 22:259, 1996.
Linda P. Dwoskin
Curriculum Vitae
Page 46
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
Wilkins L.H., Crooks P.A., Pauly J.R. and Dwoskin L.P. N-Octylnicotinium
iodide (NONI), a nicotinic receptor antagonist: competitive displacement of
[3H]nicotine binding from rat striatal membranes and brain region-specific
displacement of [3H]cytisine binding. Soc. Neurosci. Abstr. 22:260, 1996.
Dwoskin L.P., Buxton S.T. and Crooks P.A. Polyamines regulate nicotinic
receptor function in rat striatum. Soc. Neurosci. Abstr. 23:914, 1997.
Teng L.H., Cass W.A. and Dwoskin L.P. Differential effects of nicotine,
nornicotine and lobeline on striatal dopamine (DA) clearance using in vivo
electrochemistry. Soc. Neurosci. Abstr. 23:364, 1997.
Wilkins L.H., Pauly J.R., Crooks P.A. and Dwoskin L.P. N-Decylnicotinium
iodide (NDNI) inhibits nicotine-evoked 86rubidium+ (86Rb+) efflux from rat
striatal synaptosomes. Soc. Neurosci. Abstr. 23:477, 1997.
Shoaib M., Gasior M., Yasar S., Sheehan K., Dwoskin L.P. and Goldberg
S.R. Chronic caffeine exposure sensitizes rats to the locomotor activating
effects of nicotine: In vitro assessment of underlying dopaminergic
mechanisms. Soc. Neurosci. Abstr. 23:103, 1997.
Shoaib M., Dwoskin L.P. and Goldberg S.R. Food deprivation facilitates
acquisition of nicotine self-administration: Assessment of underlying
mechanisms. British Psychopharmacology Abstr., 1997.
Green T., Valone J., Dwoskin L.P., Crooks P. and Bardo M. Nornicotine
decreases self-administration of nicotine in rats. Midwestern Psychological
Association Abstr. 70:121, 1998.
Crooks P.A., Ghosheh O., Dwoskin L.P., Rogers T. and de Leon J.
Increased concentration of plasma cotinine in schizophrenic smokers
compared to normal smokers. College on Problems of Drug Dependence,
60:29, 1998.
Dwoskin L.P., Acri J.B., Crooks P.A., Teng L.H. and Witkin J.M.
Interactions of lobeline and nicotine with amphetamine: In vitro DA release
and drug discrimination in rats. College on Problems of Drug Dependence,
60:37, 1998.
Bardo M.T., Klebaur J.E., Dwoskin L.P. and Rebec G.V. Reducing drugtaking behavior with novel stimuli: evidence from laboratory animals and
implications for prevention research. Soc. Prevention Research, 6:74,
1998.
Jones M.D., Qureshi M.M., Dwoskin L.P. and Crooks P.A. Synthesis of
structurally related Lobelia Inflata alkaloids and lobeline analogues. Proc.
Amer. Chem. Soc. Abstr. MEDI-152, 1998.
Jones M.D., Qureshi M.M., Dwoskin L.P. and Crooks P.A. Synthesis of
stereochemically defined lobeline analogs as potential CNS agents.
Pharm. Sci. (Supplement) 1(1), pp.S-556, Abstract 3681,1998.
Ghosheh O.A., de Leon J., Rogers T., Dwoskin L.P. and Crooks P.A. An
HPLC method for the quantification of caffeine and major nicotine
metaboles in human plasma samples. Pharm. Sci. (Supplement) 1(1), p.S574, Abstract 3740,1998.
Dwoskin L.P., Wilkins L.H., Toller T.P., Bardo M.T. and Crooks P.A. Robust
and protracted sensitization to the locomotor effects of intermittent nicotine
Linda P. Dwoskin
Curriculum Vitae
Page 47
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
administration: Lack of antagonism by mecamylamine. Soc. Neurosci. Abstr.
24:61,1998.
Wilkins L.H., Pauly J.R., Crooks P.A. and Dwoskin L.P. N-nOctylnicotinium iodide selectively inhibits [3H]epibatidine binding:
quantitative autoradiographic analysis. Soc. Neurosci. Abstr. 24:17, 1998.
Bardo M.T., Green T.A., Valone J.M., Crooks P.A. and Dwoskin L.P.
Nornicotine is self-administered intravenously and reduces nicotine selfadministration in rats. Soc. Neurosci. Abstr. 24:137, 1998.
Green T.A., Brown R.W., Dwoskin L.P. and Bardo M.T. Effect of 6hydroxydopamine (6-OHDA) lesion in nucleus accumbens on locomotor
effects of nornicotine in rats. Soc. Neurosci. Abstr. 24:137, 1998.
Ringelberg L.S., Cass W.A. and Dwoskin L.P. Nicotine increases
dopamine clearance in rat striatum in vivo. Experimental Biol. 13:A402,
1999.
Dwoskin L.P., Chesnut M.D. and Maragos W.F. Mitochondrial toxins inhibit
dopamine uptake into rat striatal synaptosomes. Experimental Biol.
13:A402, 1999.
Maragos W.F., Jakel R.J., Chesnut M.D. and Dwoskin L.P. Does
dopamine contribute to striatal damage caused by impaired mitochondrial
function? N.Y. Acad. Sci., 1999.
Green T.A., Bardo M.T., Crooks P.A., Haubner A.J. and Dwoskin L.P.
Nornicotine evokes [3H]overflow from rat nucleus accumbens slices
preloaded with [3H]dopamine. College on Problems of Drug Dependence,
61:54, 1999.
Klebaur J.E., Neiman E.R., Phillips S.B., Bardo M.T., Crooks P.A. and
Dwoskin L.P. Lobeline decreases amphetamine and methamphetamine
self-administration in rats. College on Problems of Drug Dependence,
61:76, 1999.
Crooks P.A., Jones M.D., Chesnut M.D., Jaromczyk A.M. and Dwoskin L.P.
Stereochemically-defined lobeline analogues: Inhibition of [3H]dopamine
uptake and [3H]nicotine binding in rat striatum. College on Problems of
Drug Dependence, 61:29, 1999.
Jones M.D., Chesnut M.D., Dwoskin L.P. and Crooks P.A. Separation of
neuronal nicotinic receptor antagonist activity and dopamine uptake
inhibition by structural modification of the lobeline molecule. Proc. Amer.
Chem. Soc., MEDI 106, August, 1999.
Ayers J.T., Haubner A., Wilkins L.H., Grinevich V.P., Ghosheh O., Dwoskin
L.P. and Crooks P. A. N-Alkylated pyridine analogs: Potent and selective
antagonists at nicotinic acetylcholine receptors. 2nd International
Symposium on Nicotinic Acetylcholine Receptors: Advances in Molecular
Pharmacology and Drug Development, IBC Abstracts, 1999.
Xu R., Haubner A., Dwoskin L.P. and Crooks P.A. Synthesis of pyridino Nalkylated bridged nicotine analogues as potent nicotinic receptor
antagonists. American Association Pharmaceutical Scientists Abstr,
PharmSci (Supplement), 1(4), pp. S-404, Abstract 3142, 1999.
Linda P. Dwoskin
Curriculum Vitae
Page 48
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
Ayers J.T., Haubner A., Grinevich V.P., Ghosheh O., Dwoskin L.P. and
Crooks P.A. Evaluation of N-alkylated pyridinium analogs as antagonists at
3
American
Association Pharmaceutical Scientists Abstr., PharmSci (Supplement), 1(4),
p. S-402, Abstract 3137, 1999.
Ghosheh O., Dwoskin L.P. and Crooks P.A. Nicotine metabolites
accumulation in rat brain after peripheral nicotine administration. American
Association Pharmaceutical Scientists Abstr., PharmSci (Supplement),
1(4), pp. S-528, Abstract 3605, 1999.
Ayers J.T., Haubner A., Grinevich V.P., Dwoskin L.P. and Crooks P.A.
Synthesis and evaluation of N-alkylated pyridinium derivatives as
antagonists at the nicotinic acetylcholine receptor. Proceedings of the 219th
American Chemical Society National Meeting, Abstract No. MEDI 275,
2000.
Xu R, Ha ubner A., Grinevich V.P., Dwoskin L.P. and Crooks P.A.
Synthesis and evaluation of some conformationally restricted pyridino Nalkylated nicotine analogs as nicotinic receptor antagonists. Proceedings of
the 219th American Chemical Society National Meeting, Abstract No. MEDI
276, 2000.
Harrod S.B., Klebaur J.E., Phillips S.B., Crooks P.A., Dwoskin L.P. and
Bardo M.T. Lobeline noncompetitively inhibits methamphetamine selfadministration in rats. College on Problems of Drug Dependence 62:63,
2000.
Rauhut A.S., Chesnut M.D., Bardo M.T. and Dwoskin L.P. Reboxetine, a
highly potent and selective norepinephrine transport inhibitor, reduces
nicotine self-administration. College on Problems of Drug Dependence,
62:130, 2000.
Green T.A., Thompson M., Dwoskin L.P. and Bardo M.T. Differential
rearing alters sensitivity to stimulant properties, but not mesolimbic
dopamine metabolism in response to nicotine in rats. College on Problems
of Drug Dependence, 62:57, 2000.
Miller D.K., Green T.A., Harrod S.B., Bardo M.T., Crooks P.A. and Dwoskin
L.P. Lobeline attenuates methamphetamine and nicotine-induced
sensitization. College on Problems of Drug Dependence, 62:111, 2000.
Grinevich V.P., Xu R., Crooks P.A., Haubner A.J., Papke R. and Dwoskin
L.P. Rigid nicotine analogs provide selectivity for alpha7 subunit containing
neuronal nicotinic acetylcholine receptors. College on Problems of Drug
Dependence, 62:59, 2000.
Crooks P.A., Xu R., Grinevich V.P., Haubner A.J. and Dwoskin L.P.
Conformationally restrained analogues of NONI and NDNI are selective
antagonists at the putative alpha3beta2 nicotinic acetylcholine receptor
(nAChR) subtype. College on Problems of Drug Dependence, 62:34, 2000.
Middleton L.S., Cass W.A., Xu R., Crooks P.A. and Dwoskin L.P.
Nornicotine decreases dopamine clearance in rat striatum in vivo. The
FASEB Journal, 14:658, 2000.
Linda P. Dwoskin
Curriculum Vitae
Page 49
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
Dwoskin L.P., Ghosheh O.A. and Crooks P.A. Accumulation of nicotine
(NIC), nornicotine (norNIC) and cotinine (COT) in rat brain after peripheral
nicotine administration. The FASEB Journal, 14:659, 2000.
Dwoskin L.P., Rauhut A.S. and Bardo M.T. Reboxetine, a highly potent
and selective norepinephrine transport inhibitor reduces nicotine selfadministration in rats. 11th World Conference on Tobacco OR Health,
PO130, 127, 2000.
Dwoskin L.P., Ghosheh O., Green T., Middleton L., Teng L., Wilkins L,
Bardo M. and Crooks P.A. Nornicotine, a tobacco alkaloid and nicotine
metabolite, contributes to tobacco dependence. 11th World Conference on
Tobacco OR Health, PO240, 412, 2000.
Jones M.D., Chesnut M.D., Deaciuc G. Dwoskin L.P. and Crooks P.A.
Synthesis and pharmacology of bis-3-arylpropylamines. Proceedings of the
220th American Chemical Society National Meeting, Abstr. No. MEDI 109,
2000.
Wilkins L.H., Miller D.K., Crooks P.A. and Dwoskin L.P. Lobeline, a
nicotinic receptor antagonist. Soc. Neurosci. Abstr. 26:377, 2000.
Haubner A.J., Xu R., Grinevich V.P., Crooks P.A. and Dwoskin L.P.
Development of conformationally restricted, subtype-selective nicotinic
receptor antagonists. Soc. Neurosci. Abstr., 26:378, 2000.
Harrod S.B., Phillips S.B., Green T.A., Crooks P.A., Dwoskin L.P. and
Bardo M.T. -Lobeline attenuates methamphetamine self-administration,
but does not serve as a reinforcer in rats. Soc. Neurosci. Abstr., 26:789,
2000.
Miller D.K., Jones M.D., DeaciucA.G., Crooks P.A. and Dwoskin L.P.
Pharmacology of lobeline and meso-transdiene. Neuronal Nicotinic
Receptors, 10th Neuropharmacology Conference, P1.19, pp. 91, 2000.
Wilkins L.H., Crooks P.A., Bardo M.T. and Dwoskin L.P. Mecamylamine
(MEC) differentiates two distinct mechanisms underlying nicotine (NIC)
sensitization to once-weekly NIC injection. Neuronal Nicotinic Receptors,
10th Neuropharmacology Conference, P5.6, pp. 186, 2000.
Xu R., Grinevich V.P., Haubner A., Dwoskin L.P. and Crooks P.A.
Synthesis, characterization and evaluation of boron-containing alkaloids as
selective ligands for nicotinic acetylcholine receptors. American Association
Pharmaceutical Scientists Abstr., PharmSci (Supplement), 2(4):S-86, Abst.
2585, 2000.
Ayers J.T., Haubner A.J., Grinevich V.P., Deaciuc A.G., Dwoskin L.P. and
Crooks P.A. Evaluation of N-alkylated bis-pyridinium , bis-quinolinium, and
bis-nicotinium analogs as antagonists at the putative alpha3beta2 and
alpha4beta2 nicotinic acetylcholine receptor subtypes. American
Association Pharmaceutical Scientists Abstr., PharmSci (Supplement),
2(4):S-100, Abst. 3240, 2000.
Dwoskin L.P., Rauhut A.S., Miller D.K. and Bardo M.T. Bupropion
biphasically alters nicotine self-administration in rats and inhibits nicotineevoked dopamine release from rat striatal slices. The FASEB Journal,
15:A224, 2001.
Linda P. Dwoskin
Curriculum Vitae
Page 50
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
Middleton L.S., Cass W.A., Crooks P.A. and Dwoskin L.P. Nicotinic
receptor modulation of dopamine transporter function in striatum and medial
prefrontal cortex in rats. The FASEB Journal, 15:A558, 2001.
Mullins S.N., Rauhut A.S., Dwoskin L.P. and Bardo M.T. The effect of
acute and chronic reboxetine on nicotine self-administration in Rats.
Midwestern Psychological Association Abstr., 73:135,2001.
Gehrke B.J., Harrod S.B., Dwoskin L.P. and Bardo M.T. Intravenous
methamphetamine produces hyperactivity and single-trial conditioned place
preference: Effect of lobeline pretreatment. Midwestern Psychological
Association Abstr., 73:22, 2001.
Allen D.D., Smith Q.R., Roder K.E., Dwoskin L.P., Crooks P.A. Enhanced
brain drug delivery of a neuroactive nicotine analogue by the blood-brain
barrier choline transporter. Cerebrovascular Biol., 2001.
Crooks P.A., Xu R., Dwoskin L.P., Grinevich V.P. and Deaciuc G. Nicotinic
acetylcholine receptor binding affinities of boron-containing nicotine
analogs. Drug and Alcohol Dependence, 63:S35, Abstr. 130, 2001.
Zhu J., Ayers J.T., Ghosheh O., Crooks P.A. and Dwoskin L.P. N-nAlkylnicotinium and N-n-alkylpyridinium analogs inhibit [3H]dopamine uptake
into rat striatal synaptosomes. Drug and Alcohol Dependence, 63:S177,
Abstr. 726, 2001.
Harrod S.B., Crooks P.A., Jones M.D. and Dwoskin L.P. Defunctionalized
structural analogs of alpha-lobeline inhibit [3H]dopamine uptake into rat
striatal synaptosomes. Drug and Alcohol Dependence, 63:S63, Abstr. 244,
2001.
Grinevich V.P., Crooks P.A., Sumithran S.P., Deaciuc A.G., Xu R., Yokel
R.A. and Dwoskin L.P. Effect of introducing unsaturation into the N-alkyl
chain of N-octylnicotinium iodide (NONI) and N-decylnicotinium iodide
(NDNI) on inhibition of neuronal nicotinic receptors. Soc. Neurosci. Abstr.,
31:249, Abstr. 485.7, 2001.
Harrod S.B., Crooks P.A., Zhu J. and Dwoskin L.P. Meso-Transdiene, a
defunctionalized analog of lobeline, inhibits dopamine and serotonin uptake
into rat striatal and hippocampal synaptosomes. Soc. Neurosci. Abstr.,
31:418, Abstr. 814.1, 2001.
Miller D.K., Crooks P.A., Zheng G., Deaciuc A.G. and Dwoskin L.P. Potent
4

2* neuronal nicotinic receptors by lobeline
analogs. Soc. Neurosci. Abstr., 31: 344, Abstr. 667.8, 2001.
Green T.A., Miller D.K., Wong M.K., Harrod S.B., Crooks P.A., Bardo M.T.
and Dwoskin L.P. Lobeline attenuates methamphetamine and cocaine selfadministration and locomotor sensitization in rats. Soc. Neurosci. Abstr.,
27:453, Abstr. 878.1, 2001.
Zhu J., Green T.A., Bardo M.T. and Dwoskin L.P. Differential rearing alters
sensitivity to the effects of GBR12935 on locomotor activity, but not
dopamine transporter function. Soc. Neurosci. Abstr., 27:278, Abstr.
540.13, 2001.
Bardo M.T., Rauhut A.S., Mullins S.N. and Dwoskin L.P. Effect of
reboxetine on nicotine self-administration and reinstatement: Preclinical
Linda P. Dwoskin
Curriculum Vitae
Page 51
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
evidence for a novel smoking cessation pharmacotherapy. Soc. Neurosci.
Abstr., 31:344, Abstr. 667.2 2001.
Xu R., Dwoskin L.P., Grinevich V.P., Sumithran S.P., Deaciuc A.G., Crooks
P.A. Synthesis and evaluation of pyridino-N-unsaturated, branched, and
cycloalkyl nicotine analogs as nicotinic receptor antagonists. American
Association Pharmaceutical Scientists, PharmSci (Supplement), Abstr.
M2332, pp.138, 2001.
Zheng G., Harrod S.B., Dwoskin L.P. and Crooks P.A. Synthesis and
evaluation of some novel heterocycles as antagonists at the dopamine
transporter. American Association Pharmaceutical Scientists, PharmSci
(Supplement), Abstr. M2384, pp.139, 2001.
Hojahmat M., Miller D.K., Deaciuc A.G., Jones M.D., Zheng G., Dwoskin
L.P. and Crooks P.A. Synthesis, characterization and evaluation of novel
analogs of (-)-lobeline as antagonists at nicotinic acetylcholine receptor
subtypes. American Association Pharmaceutical Scientists, PharmSci
(Supplement), Abstr. M22225, pp.137, 2001.
Ayers J.T., Haubner A., Sumithran S.P., Grinevich V.P., Deaciuc A.G.,
Ghosheh O., Dwoskin L.P. and Crooks P.A. Synthesis and evaluation of
N-alkylpyridinium analogs as antagonists at nicotinic acetylcholine receptor
subtypes. American Association Pharmaceutical Scientists, PharmSci
(Supplement), Abstr. M2340, pp.139, 2001.
Ayers J.T., Haubner A., Sumithran S.P., Grinevich V.P., Deaciuc A.G.,
Dwoskin L.P. and Crooks P.A. Synthesis and evaluation of bis-pyridinium,
bis-quinolinium and bis-nicotinium analogs as antagonists at nicotinic
acetylcholine receptor subtypes. American Association Pharmaceutical
Scientists, PharmSci (Supplement), Abstr. M2328, pp.138, 2001.
Allen D.D., Smith Q.R., Roder K.E., Dwoskin L.P. and Crooks P.A. Site
directed brain drug delivery of a neuroactive nicotine analog using the
blood-brain barrier choline carrier. American Association Pharmaceutical
Scientists, PharmSci (Supplement), Abstr. T3321, pp.152, 2001.
Wei X., Dwoskin L.P., Deaciuc A.G. and Crooks P.A. Isolation,
identification and synthesis of several new minor tobacco alkaloids and their
affinities for different subtypes of neuronal nicotinic receptors. American
Association Pharmaceutical Scientists, PharmSci (Supplement), Abstr.
M2375, pp.139, 2001.
Dwoskin L.P., Rauhut A., Miller D.K.,and Bardo M.T. Bupropion
biphasically alters nicotine self-administration in rats and inhibits nicotineevoked dopamine and norepinephrine release from rat striatal and
hippocampal slices via an interaction with nicotinic receptors. Gordon
Research Conference on Catecholamines, 2001.
Middleton, L.S., Cass W.A., Crooks P.A and Dwoskin L.P. Nicotinic
receptor modulation of dopamine transporter (DAT) function in striatum and
medial prefrontal cortex in rats. Gordon Research Conference on
Catecholamines, 2001.
Zhu J., Green T.A., Bardo M.T. and Dwoskin L.P. Effect of environmental
enrichment on nicotine-induced locomotor activity and dopamine clearance
Linda P. Dwoskin
Curriculum Vitae
Page 52
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
in the medial prefrontal cortex using in vivo voltammetry. The FASEB
Journal 16:A585, 2002.
Middleton L.S. and Dwoskin L.P. Tolerance develops to the nicotine
enhancement of dopamine clearance in medial prefrontal cortex. The
FASEB Journal, 16:A585, 2002.
Dwoskin L.P., Miller D.K., Zheng G., Norrholm S.D., Grinevich V.P. and
Crooks P.A. Meso-transdiene, a potent, selective antagonist at alpha3*containing nicotinic receptors. Drug and Alcohol Dependence 64:38, 2002.
Norrholm S.D., Miller D.K., Hojahmat M., Crooks P.A. and Dwoskin L.P. 8Hydroxyl esterification of lobeline increases selectivity for the alpha4beta2*
subtype of nicotinic receptor, while increasing affinity for dopamine and
serotonin transporters. Drug and Alcohol Dependence 64:25, 2002.
Miller D.K. and Dwoskin L.P. Mechanism of bupropion and reboxetine
antagonism of nicotinic receptors in rat brain. Drug and Alcohol
Dependence 64:85, 2002.
Harrod S.B., Miller D.K., Bardo M.T. and Dwoskin L.P. Effect of
continuous-release lobeline on methamphetamine-induced hyperactivity and
methamphetamine self-administration in rats. Drug and Alcohol
Dependence 64: 34, 2002.
Rauhut A.S., Dwoskin L.P. and Bardo M.T. Bupropion dose dependently
and selectively increases nicotine self-administration in rats. Drug and
Alcohol Dependence 64:39, 2002.
Crooks P.A., Ayers J.T., Haubner A.J., Grinevich V.P., Sumithran S.P.,
Deaciuc A.G. and Dwoskin L.P. The bis-picolinium salt, bPiDDB, is a
potent and selective antagonist at nicotinic acetylcholine receptors
mediating nicotine-evoked dopamine release in rat striatum. Drug and
Alcohol Dependence 64:38, 2002.
Dwoskin L.P., Grinevich V.P., Xu R., Ayers J.T. and Crooks P.A. Novel
subtype-selective nicotinic receptor (nAChR) antagonists. XIVth World
Congress of Pharmacology, Abstr. 32.23, pp. 27, 2002.
Dwoskin L.P., Miller D.K. Zheng G., Grinevich V.P., Norrholm S.D., Harrod
S.B., Bardo M.T. and Crooks P. A. Lobeline: A potential treatment for
psychostimulant abuse using VMAT2 as a novel Target. Dopamine 2003,
Satellite Meeting of the XIVth World Congress of Pharmacology, Abstr.
P2.13, pp 135, 2002.
Zhu, J., Xu R, Ayers J.T., Crooks P.A. and Dwoskin .L.P. Interaction of Nn 2*nicotinic receptors and dopamine
transporters. Soc. Neurosci. Abstr. 32:745.16, 2002.
Norrholm S.D., Miller D.K., Hojahmat M., Crooks P. A. and Dwoskin L.P.
Interaction of meso-transdiene with nicotinic receptors and dopamine
transporters: The importance of side chain unsaturation. Soc. Neurosci.
Abstr. 32:807.2, 2002.
Neugebauer N.M., Miller D.K. and Dwoskin L.P. Central administration of
lobeline potentiates methamphetamine-induced hyperactivity in rats. Soc.
Neurosci. Abstr. 32:401.12, 2002.
Linda P. Dwoskin
Curriculum Vitae
Page 53
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
Grinevich V.P., Crooks P.A., Zheng G., Hojahmat M. and Dwoskin L.P.
Interaction of Lobelia Inflata alkaloids and synthetic analogs with the
vesicular monoamine transporter-2. Soc. Neurosci. Abstr. 32:343.7, 2002.
Green T.A., Dwoskin L.P. and Bardo M.T. Individual differences in
locomotor activity and operant responding for sucrose or cocaine in
environmentally enriched or isolated rats. Soc. Neurosci. Abstr. 32:501.6,
2002.
Zheng G., Grinevich V.P., Dwoskin L.P. and Crooks P.A. Synthesis and
evaluation of novel (-)-lobeline analogs at ligands at the tetrabenazine site
of the vesicular monoamine transporter (VMAT2). American Association
Pharmaceutical Scientists, PharmSci (Supplement), 4 (4) Abstr M1152,
2002.
Hojahmat M., Norrholm S.D., Miller D.K., Dwoskin L.P. and Crooks P.A.
Synthesis and evaluation of (-)-lobeline analogs as antagonists at neuronal
nicotinic acetylcholine receptors. American Association Pharmaceutical
Scientists, PharmSci (Supplement), 4 (4) Abstr M1191, 2002.
Wei, X., Crooks P.A., and Dwoskin L.P. Synthesis of novel 2-aryl
substituted pyrrolidines and their affinities for neuronal nicotinic
acetylcholine receptor subtypes. American Association Pharmaceutical
Scientists, PharmSci (Supplement), 4 (4) Abstr M1145, 2002.
Miller D.K., Zheng G., Norrholm S.D., Grinevich V.P., Crooks P.A. and
Dwoskin L.P. Development of novel pharmacotherapies for
methamphetamine abuse: cis-lobelane, an analog of lobeline. Experimental
Biology ‘03, Abst 140.7, pp. 53, 2003.
Sumithran S.P., Crooks P.A., Deaciuc G.A., Ayers J.T. and Dwoskin L.P.
Development of a pharmacotherapy for tobacco use cessation: bPiDDB, a
3 2* nicotinic receptor antagonist.
Experimental Biology ’03, Abst. 390.10, pp. 151, 2003.
Middleton L.S. and Dwoskin L.P. Systemic ncitone enhances in vivo
dopamine (DA) clearance in striatum and increases DA transport capacity
(Vmax) in striatal synaptosomes. Drug and Alcohol Dependence 65:10,
2003.
Crooks P.A., Xu R., Deaciuc A.G., Sumithran S.P. and Dwoskin L.P.
Structural modification of the alkyl chain of N-n-alkylnicotinium compounds:
Affinity for alpha4beta2* nicotinic receptors. Drug and Alcohol Dependence
65:10, 2003.
Zhu J., Apparsundaram S., Bardo M.T. and Dwoskin L.P. Environmental
enrichment reduces dopamine transporter function and cell surface
expression in the rat medial prefrontal cortex. Soc. Neurosci. Abstr.
33:198.3Su, 2003.
Norrholm S.D., Zhang G., Deaciuc J., Zhu J., Crooks P.A. and Dwoskin
L.P. Interaction of Cis-lobelane and its analogs at the vesicular monoamne
transporter (VMAT2). Soc. Neurosci. Abstr., 33:961.2We, 2003.
Harrod S.B., Neugebauer N.M., Dwoskin L.P. and Bardo M.T. The effects
of nicotine on methamphetamine self-administration and methamphetamine
drug seeking behavior in rats. Soc. Neurosci. Abstr., 33:424.9Mo, 2003.
Linda P. Dwoskin
Curriculum Vitae
Page 54
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
Neugebauer N.M., Helton M., Dwoskin L.P., and Cassis L.A. Central
angiotensin II reduces food intake and body weight in rats. Soc. Neurosci.
Abstr., 33:831.8 We, 2003.
Dwoskin L.P., Sumithran S.P., Ayers J.T. and Crooks P.A. Development of
novel treatments for nicotine addiction: bis-Picolinium, a very potent and
selective antagonist at nicotinic receptor subtypes mediating nicotineevoked dopamine release. 9:4, Abst. POS3-13 Soc. Res. Nicotine and
Tobacco, 2003.
Zheng G, Norrholm S.D., Deaciuc A.G., Zhu J., Dwoskin L.P. and Crooks
P.A. Synthesis, characterization and evaluation of novel lobelane analogs
at the vesicular monoamine transporter (VMAT2)”, American Association
Pharmaceutical Scientists, PharmSci (Supplement), 5, (4) Abstract M1146,
2003.
Hojahmat M., Norholm S.D., King M., Dwoskin L.P. and Crooks P.A.
Aromatic sulfonic acid esters of (-)-2R,6S,8S-lobeline act as antagonists at
42* and 362* nicotinic receptors”, American Association
Pharmaceutical Scientists, PharmSci (Supplement), 5, (4) Abstract M1137,
2003.
Dwoskin L.P., Zhu J., Apparsundaram S. and Bardo M.T. Environmental
enrichment decreases dopamine transporter function and cell surface
expression in the rat medial prefrontal cortex. Frontiers in Addiction
Biology-Genomics and Beyond, Vanderbilt University Summer Conference,
2004.
Middleton L.S., Deaciuc A.G. and Dwoskin L.P. Nicotine increases
dopamine clearance in vivo and DAT efficiency in vitro. Frontiers in
Addiction Biology-Genomics and Beyond, Vanderbilt University Summer
Conference, 2004.
Krishnamurthy S., Crooks P.A., Zheng G. and Dwoskin L.P.
Defunctionalized lobeline analogs inhibit methamphetamine-evoked
dopamine release from rat striatal slices, Frontiers in Addiction BiologyGenomics and Beyond, Vanderbilt University Summer Conference, 2004.
Sumithran S.P., Zhu J., Deaciuc A.G., Xu R., Crooks P.A. and Dwoskin
L.P. The unsaturated N-n-alkylnicotinium analog, NONB3t, is a potent and
selective antagonist at nicotinic receptors (62*) mediating nicotineevoked [3H]dopamine release from rat striatal slices. Frontiers in Addiction
Biology-Genomics and Beyond, Vanderbilt University Summer Conference,
2004.
Zhu J., Bardo M.T. and Dwoskin L.P. Environmental enrichment
differentially alters nicotine-induced enhancement of dopamine clearance in
rat nucleus accumbens shell and core. Frontiers in Addiction BiologyGenomics and Beyond, Vanderbilt University Summer Conference, 2004.
Zhu J., Bardo M.T. and Dwoskin L.P. Environmental enrichment
differentially alters nicotine-induced enhancement of dopamine clearance in
rat nucleus accumbens shell and core. College on Problems of Drug
Dependence, 66:53, Abst. 37, 2004.
Linda P. Dwoskin
Curriculum Vitae
Page 55
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
Zheng G., Norrholm S.D., Dwoskin L.P. and Crooks P.A. Synthesis and
comparative pharmacological activities of lobelane isomers at VMAT2.
College on Problems of Drug Dependence, 66:34, Abst. 36, 2004.
Krishnamurthy S., Norrholm S.D., Zheng G, Crooks P.A. and Dwoskin L.P.
Lobelane, a potent lobeline analog, inhibits methamphetamine-evoked
dopamine release from rat striatal slices”, College on Problems of Drug
Dependence, 66:34, Abstr. 37, 2004.
Neugebauer N.M., Harrod S.B., Stairs D.J., Zheng G., Crooks P.A.,
Dwoskin L.P. and Bardo M.T. Effects of lobelane on methamphetamine
self-administration and sucrose-maintained responding. College on
Problems of Drug Dependence, 66:34, Abstr. 38, 2004.
Sumithran S.P., Crooks P.A., Zhu J., Zheng G., Papke R.L. and Dwoskin
L.P. Nicotine-boron: A novel potent antagonist at alpha6beta2* nicotinic
receptors in rat striatum. College on Problems of Drug Dependence, 66:53,
Abstr. 35, 2004.
Wei X., Stairs D.J., Neugebauer N.M., Bardo M.T., Dwoskin L.P. and
Crooks P.A. A new method for GC/MS quantification of nornicotine in rat
brain and blood after acute subcutaneous pretreatment with nornicotine
enantiomers. College on Problems of Drug Dependence, 66:53, Abstr. 38,
2004.
Stairs D.J., Neugebauer N.M., Wei X., Crooks P.A., Dwoskin L.P. and
Bardo M.T. Enantiomeric effects of nornicotine on nicotine selfadministration and sucrose-maintained responding in rats. College on
Problems of Drug Dependence, 66:53, Abstr. 39, 2004.
Sumithran S.P., Crooks P.A., Deaciuc A.G., Ayers J.T. and Dwoskin L.P.
Bis-Quinolinium and bis-isoquinolinium auaternary ammonium analogs
potently inhibit nicotinic receptors mediating nicotine-evoked striatal
dopamine release. Soc. Neurosci. Abstr., 34: Abstract 918.12-W, 2004.
Zhu J., Bardo M.T. and Dwoskin L.P. Environmental enrichment reduces
dopamine transporter function and cell surface expression in the rat medial
prefrontal cortex. Soc. Neurosci. Abstr. 34: Abstract 580.4-M, 2004.
Krishnamurthy S., Lakhlani S.P., Jennes L.H. and Dwoskin L.P. Estrous
cycle phase regulation of nicotine-evoked [3H]dopamine release from
superfused rat striatal slices. Soc. Neurosci. Abstr. 34: 575.8-M, 2004.
Zhu J. and Dwoskin L.P. Nicotine increases dopamine transporter function
in rat prefrontal cortex. 14th Neuropharmacology Conference, 2004.
Neugebauer N.M., Ayers J.T., Crooks P.A., Dwoskin L.P. and Bardo M.T.
The effects of N,N’-dodecane-1,12-diyl-bis-3-picolinium dibromide
(bPiDDB), a novel nicotinic antagonist, on nicotine-induced behaviors. 10th
Annual Duke Nicotine Research Conference Abstr. 2004.
Zheng G., Dwoskin L.P., Krishnamurthy S. and Crooks P.C. Synthesis and
pharmacological studies of meso-transdiene (MTD) and lobelane
stereoisomers to inhibit methamphetamine-evoked dopamine release from
rat striatal slices. American Association Pharmaceutical Scientists,
PharmSci (Supplement), Abstract W4117, pp. 97, 2004.
Linda P. Dwoskin
Curriculum Vitae
Page 56
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
Zheng F., Ayers J.T., Schmitt J.D., Zhan C.G., Dwoskin L.P. and Crooks
P.A. Computational neural network (NN) prediction of the antagonist activity
of mono- and bis-quaternary ammonium salts at the 62* (dopamine
releasing) nAChR subtype. American Association Pharmaceutical
Scientists, PharmSci (Supplement), Abstract W4116, pp. 97, 2004.
Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P. and Bardo M.T.
Effect of a novel nicotinic receptor antagonist N,N’dodecane-1,12-diyl-bis-3picolinium bibromide (bPiDDB) on nicotine self-administration, sucrosemaintained respond and locomotor activity in rats. College on Problems of
Drug Dependence, 67, Abst 100, p53, 2005.
Crooks P.A., Zheng G., Deaciuc A.G., Zheng F. and Dwoskin L.P. Long
chain N-n-alkylnicotinium analogs inhibit nicotinic receptors probed by
[3H]nicotine binding, but not [3H]methyllycaconitine binding to rat brain
membranes. College on Problems of Drug Dependence, 67, Abst. 915, p77,
2005.
Bruntz R.C., Zhu J., Apparsundaram and Dwoskin L.P. Nicotine increases
dopamine transporter function and cell surface expression in rat prefrontal
cortex. College on Problems of Drug Dependence, 67, 2005.
Zhu J., Cain M.E., Bardo M.T. and Dwoskin L.P. Individual differences in
nicotine modulation of the dopamine transporter in prefrontal cortex and in
the locomotor stimulant effects of nicotine. College on Problems of Drug
Dependence, 67, 2005.
Williams Y. and Dwoskin L.P. Effect of acute and chronically administered
lobeline or methylphenidate on dopamine transporter function. College on
Problems of Drug Dependence, 67, 2005.
Dwoskin L.P., Sumithran S.P., Neugebauer N.M., Zheng G., Deaciuc A.G.,
Crooks P.A. and Bardo M.T. Pharmacology of the bis-picolinium analog
bPiDDB: a lead compound in the development of novel subtype-selective
nicotinic receptor antagonist as treatemtns for somoking cessation.
European Conference Society for Research on Nicotine and Tobacco, 2005.
Huang X., Zheng F., Crooks P.A., Dwoskin L.P. and Zhan C.G. Multiple
species of nicotine and deschloroepibatidine interacting with the α4β2
nicotinic acetylcholine receptor: From microscopic binding to
phenomenological binding affinity. American Association Pharmaceutical
Scientists, PharmSci (Supplement), Vol. 7, No. S2, Abstract M1122, 2005.
Zhu J, Bruntz R.C., Apparsundaram S and Dwoskin L.P. Nicotine
increases dopamine transporter cell surface expression in rat prefrontal
cortex and increases [3H]dopamine uptake via a nicotinic receptor-mediated
mechanism. Soc. Neurosci. Abstr, 35: Abstract 269.12-Su, 2005.
Rahman S, Neugebauer M, Zhang A, Crooks P.A., Dwoskin L.P. and
Bardo M.T. Effects of novel N,N’-dodecane-1,12-diyl-bis-3-picolinium
dibromide on acute nicotine-induced changes in brain dopamine function.
Soc. Neurosci. Abstr, 35: Abstract 158.15-Su, 2005.
Dwoskin L.P., Dhawan G.K., Zheng G., Deaciuc A.G., Krishnamurthy S,
Crooks P.A. Effect of lobeline analogs to inhibit nicotine- and
methamphetamine-evoked dopamine overflow from rat striatal slices: novel
Linda P. Dwoskin
Curriculum Vitae
Page 57
193.
194.
195.
196.
197.
198.
199.
200.
201.
therapeutic agents with potential for the treatment of psychostimulant
abuse. Soc. Neurosci. Abstr, 35: Abstract 681.17-T, 2005.
Sumithran S.P., Dhawan G.K., Zheng G., Crooks P.A. and Dwoskin L.P.
The novel nicotinic receptor antagonist N,N’-dodecane-1,12-diyl-bis-3picolinium dibromide (bPiDDB) inhibits nicotine-evoked [3H]norepinephrine
overflow fromsuperfused rat hippocampal slices. Soc. Neurosci. Abstr, 35:
Abstract 961.17-W, 2005.
Horton D.B., Hojahmat M., Norrholm S.D., Dhawan G.K., Crooks P.A. and
Dwoskin L.P. Sulfate esters of lobeline: interaction at neurotransmitter
transporters and nicotinic receptors. Soc. Neurosci. Abstr, 35: Abstract
227.11-Su, 2005.
Zhang Z. Sumithran S.P., Deaciuc A.G., Dwoskin L.P. and Crooks P.A. NAlkylpyridinium- and bis-N, N-alkylpyridinium analogs as nicotinic receptor
antagonists: Selective inhibition of neuronal nicotinic acetylcholine receptor
subtypes that mediate nicotine-evoked dopamine release. American
Association Pharmaceutical Scientists, PharmSci (Supplement), Vol. 7, No.
S2, Abstract W4080, 2005.
Zheng G, Horton D, Dwoskin L.P. and Crooks P.A. Synthesis and
pharmacological studies of mono-hydroxy lobeline analogs to inhibit [3H]5hydroxytryptamine and [3H]dopamine uptake into rat hippocampal and
striatal synaptosomes. American Association Pharmaceutical Scientists,
PharmSci (Supplement), Vol. 7, No. S2, Abstract T2125, 2005.
Zhang Z, Lockman P.R., Geldenhuys W.J., Allen D.D., Dwoskin L.P. and
Crooks P.A. Synthesis of bis-pyridinium analogs and structurally related
cyclophanes with high affinity for the blood brain barrier choline transporter.
American Association Pharmaceutical Scientists, PharmSci (Supplement),
Vol. 7, No. S2, Abstract W4079, 2005.
Thomas F.C., Geldenhuys W.J., Lockman P.R., Nguyen T.H., Van Der
Schyf C.J., Crooks P.A., Dwoskin L.P., Allen D.D. 3D-QSAR studies on
the affinity of semirigid bis-quaternary nicotinuim compounds for the blood
brain barrier choline transporter. American Association Pharmaceutical
Scientists, PharmSci (Supplement), Vol. 7, No. S2, Abstract R62021, 2005.
Zheng F., Zheng G., Deaciuc A., Dwoskin L.P. and Crooks P.A. QSAR
study on the affinity of lobeline analogs for the vesicular monoamine
transporter-2 (VMAT-2) within the presynaptic terminal. American
Association Pharmaceutical Scientists, PharmSci (Supplement), Vol. 7, No.
S2, Abstract T2124, 2005.
Hojahmat M., Wei X., Dwoskin L.P., Bardo M.T., and Crooks P.A. A novel
synthesis of R(+)-nornicoitne, a potential smoking cessation agent, via Ndemethylation of R(+)-nicotine. American Association Pharmaceutical
Scientists, PharmSci (Supplement), Vol. 7, No. S2, Abstract W4068, 2005.
Dwoskin L.P., Zhu J., Cain M.E. and Bardo M.T. Individual differences in
nicotine-induced hyperactivity and nicotine-induced augmentation of
dopamine transporter function and trafficking to the cell surface in prefrontal
cortex in rats. European Behavioural Pharmacology Society Meeting,
Abstract 104, 2005.
Linda P. Dwoskin
Curriculum Vitae
Page 58
202.
203.
204.
205.
206.
207.
208.
209.
Bardo M.T., Rebec G.V. and Dwoskin L.P. Enriched environments and
drug abuse vulnerability. European Behavioural Pharmacology Society
Meeting, Abstract S17, 2005
Papke R.L., Dwoskin L.P. and Crooks P.A. Differing activity profiles of
nicotine and its CNS metabolite and tobacco alkaloid, nornicotine. Soc.
Res. Nicotine and Tobacco, 2006.
Wooters T.E., Dwoskin L.P. and Bardo M.T. Effects of methylphenidate in
male and female rats classified as high of low responders. Soc. Res.
Nicotine and Tobacco, 2006.
Zhang Z., Deaciuc A.G., Lockman P.R., Allen D.D., Dwoskin L.P. and
Crooks P.A. Synergistic design of polar bis-pyridinium analogs containing a
1,4-di-(1-butynyl)phenylenediyl linker: Interaction with both nicotinic
receptors and the blood-brain barrier choline transporter (BBBCT). College
on Problems of Drug Dependence, 69, p 17, 2006.
Zheng G., Sumithran S.P., Deaciuc A.G., Dwoskin L.P. and Crooks P.A.
New leads for the treatment of nicotine addiction: Discovery of novel bisquaternary ammonium antagonists at neuronal nicotinic receptors mediating
nicotine-evoked dopamine release. College on Problems of Drug
Dependence, 69, Abstract 24, p27, 2006.
Papke R.L., Zheng G., Burkle C.J., Crooks P.A. and Dwoskin L.P. Novel
trivalent antagonists with selectivity for alpha7 nicotinic acetylcholine
receptors. College on Problems of Drug Dependence, 69, Abstract 23, p27
2006.
Sumithran S.P., Zheng G., Deaciuc A.G., Crooks P.A. and Dwoskin L.P.
New leads for the treatment of nicotine addiction: Discovery of novel trisquaternary ammonium antagonists at neuronal nicotinic receptors mediating
nicotine-evoked dopamine release. College on Problems of Drug
Dependence, 69, Abstract 25, p27, 2006.
Rahman S., Neugebauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P. and
Bardo M.T. Effects of novel N,N’-dodecane-1,12-diyl-bis-3-picolinium
dibromide (bPiDDB) on nucleus accumbens dopamine release in rats
sensitized to nicotine. College on Problems of Drug Dependence, 69,
Abstract 45, p5, 2006.
210.
Zhu J., Bruntz R.C., Apparsundaram S. and Dwoskin L.P. Nicotinic
receptor activation increases [3H]dopamine uptake and cell surface
expression of dopamine transporters in rat prefrontal cortex. IVXth
International Congress of Pharmacology, 2006.
211.
Zhang Z., Sumithran S.P., Deaciuc A.G., Lockman P.R., Allen D.D.,
Dwoskin L.P. and Crooks P.A. Synergistic design of polar bis-pyridinium
analogs containing a conformationally restricted 1,4-di-(1butynyl)phenylenediyl linker: interaction with both nicotinic receptors and the
blood-brain barrier choline transporter (BBBCT). American Association
Pharmaceutical Scientists, PharmSci (Supplement), Abstract M1116, 2006.
Zheng G., Sumithran S.P., Papke R.L., Dwoskin L.P., Crooks P.A.
Synthesis and pharmacological studies of novel tris-quaternary ammonium
212.
Linda P. Dwoskin
Curriculum Vitae
Page 59
213.
214.
215.
216.
217.
218.
219.
220.
221.
222.
salts: Interaction with nicotinic acetylcholine receptors and inhibition of
nicotine-evoked dopamine release. American Association Pharmaceutical
Scientists, PharmSci (Supplement), Abstract M1130, 2006.
Vartak A.P., Dwoskin L.P. and Crooks P.A. Synthetic approaches towards
analogs of lobeline: Discovery of novel treatments for psychostimulant
abuse. American Association Pharmaceutical Scientists, PharmSci
(Supplement), Abstract M1093, 2006.
Zheng F., Deaciuc A.G., Zheng G., Zhan C.G., Dwoskin L.P. and Crooks
P.A. Prediction of the affinity of N-n-alkyl nicotinium salts as antagonists at
the α4β2* nicotinic acetylcholine receptor (nAChR) subtype by
Computational Neural Network Analysis. American Association
Pharmaceutical Scientists, PharmSci (Supplement), Abstract M1128, 2006.
Albayati Z.A.F., Neugebauer N., Bardo M.T., Dwoskin L.P. and Crooks
P.A. Pharmacokinetics, metabolism and brain/plasma bioavailability of N,N’dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), a novel nicotinic
receptor antagonist. American Association Pharmaceutical Scientists,
PharmSci (Supplement), Abstract M1091, 2006.
Lockman P.R., Crooks P.A., Manda V., Thomas F., Dwoskin L.P. and Allen
D.D. The blood-brain barrier choline transporter facilitates brain entry of a
polar nicotinic receptor antagonist, bis-[dodecane-1,12-diyl]-3-picolinium
dibromide (bPiDDB). American Association Pharmaceutical Scientists,
PharmSci (Supplement), Abstract W5337, 2006.
Geldenhuys W.J., Manda V., Lockman P.R., Crooks P.A., Dwoskin L.P.
and Allen D.D. Molecular modeling of semi-rigid bis-quaternary ammonium
nicotinium compounds at the blood brain barrier choline transporter.
American Association Pharmaceutical Scientists, PharmSci (Supplement),
Abstract W5344, 2006.
MandaV.K., Egbert J., Crooks P.A., Dwoskin L.P., Allen D.D. and Lockman
P.R. Affinity of nicotinic receptor antagonists for the blood-brain barrier
choline transporter: A potential vector for brain access. American
Association Pharmaceutical Scientists, PharmSci (Supplement), Abstract
W5345, 2006.
Haubner A., Littleton J.M., Millar N., Dwoskin L.P. and Crooks P.A. Subtype selective, guanylated nicotine analogs: Functionally active noncompetitive agonists and antagonists at the neuronal nicotinic receptor.
American Association Pharmaceutical Scientists, PharmSci (Supplement),
Abstract M1098, 2006.
Papke R.L., Dwoskin L.P. and Crooks P.A. Nornicotine, the tobacco
alkaloid, and CNS metabolite of nicotine, differentially activates brain
nicotine receptors. Soc. Neurosci. Abstr, 36: Abstract 524.11/C74, 2006.
Wooters T.E., Dwoskin L.P. and Bardo M.T. Discriminative stimulus effects
of N-methyl-D-aspartate antagonist in methamphetamine-trained rats. Soc.
Neurosci. Abstr, 36: Abstract, 2006.
Kantak K.M., Singh T., Kerstetter K.A., Deschepper C.F. and Dwoskin L.P.
Advancing the SHR strain as an animal model of ADHD: Evidence for
Linda P. Dwoskin
Curriculum Vitae
Page 60
neurocognitive deficits in orbitofrontal cortex- and dorsal striatum-dependent
tasks. Soc. Neurosci. Abstr, 36: Abstract, 2006.
223. Lockman P.R., Crooks P.A., Egbert J., Thomas F., Dwoskin L.P. and Allen
D.D. Facilitated distribution of the charged nicotinic receptor antagonist bis[dodecane-1,12-diyl]-3-picolinium dibromide (bPiDDB) across the bloodbrain barrier. Soc. Neurosci. Abstr, 36: Abstract 460.12/EE10, 2006.
224. Manda V.K., van der Schyf C.J., Crooks P.A., Dwoskin L.P., Allen D.D. and
Lockman P.R. Determination of novel nicotinic receptor antagonist binding
to the blood-brain barrier choline transporter: a potential mechanism for
brain entry. Soc. Neurosci. Abstr, 36: Abstract, 2006.
225. Zhu J., Bardo M.T. and Dwoskin L.P. Environmental enrichment:
Differential subcellular distribution of vesicular monoamine transporter-2
(VMAT2) in prefrontal cortex. Soc. Neurosci. Abstr, 36: Abstract, 2006.
226. Horton D.B., Hojahmat M., Deaciuc G., Culver J., Norrholm S.D., Crooks
P.A. and Dwoskin L.P. Lobeline and meso-transdiene analogs: interaction
at neurotransmitter transporters and nicotinic receptors. Soc. Neurosci.
Abstr, 36: Abstract 591.1/PP67, 2006.
227. Neugebauer N.M., Geary E.D., Dwoskin L.P., Bardo M.T. Lobeline blocks
cocaine conditioned place preference and cocaine-induced hyperactivity.
Soc. Neurosci. Abstr, 36: Abstract, 2006.
228. Neugebauer N.M., Geary E.D., Dwoskin L.P., Bardo M.T. Lobeline
decreases methamphetamine conditioned place preference and locomotor
activity. Keystone Symposia: Neurobiology of Addiction, 2006.
229. Dwoskin L.P., Zhu J. and Bardo M.T. Environmental enrichment alters
dopamine transporter and vesicular monoamine transporter function and
cellular localization. Keystone Symposia: Neurobiology of Addiction, 2006.
230. Albayati Z.F., Dwoskin L.P., Crooks P.A. Pharmacokinetics of N,N’doceane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), a novel nicotinic
receptor antagonist. American Association Pharmaceutical Scientists,
Abstract, 2007.
231. Chagkutip J., Vartak A.P., Deaciuc A.G., Crooks P.A., Dwoskin L.P. Novel
Vesicular monoamine transporter (VMAT2) inhibitors as potential treatments
for methamphetamine abuse: constrained lobelane analogs inhibit VMAT2
binding and function. Soc. Neurosci. Abstr, Abstract, 2007.
232. Culver J.P., Deaciuc A.G., Dwoskin L.P., Crooks P.A. Design and
synthesis of lobelane analogs targetting the vesicular monoamine
transporter (VMAT2) as a potential treatment for methamphetamine abuse.
American Chemical Society Abstract MEDI-268, 2007.
233. Deaciuc A.G., Horton D.B., Hojahmat M., Culver J.P., Norrholm S.D.,
Crooks P.A., Dwoskin L.P. Novel vesicular monoamine transporter
(VMAT2) inhibitors as potential treatments for methamphetamine abuse: 3,
5-disubstituted meso-transdiene analogs of lobeline. Soc. Neurosci. Abstr,
Abstract, 2007.
234. Dwoskin L.P., Apparsundaram S., Yokel R.A., Zhu J. Acute and chronic
nicotine administration decreases dopamine transporter function in rat
prefrontal cortex and striatum. Soc. Neurosci. Abstr, Abstract, 2007.
Linda P. Dwoskin
Curriculum Vitae
Page 61
235.
236.
237.
238.
239.
240.
241.
242.
243.
244.
245.
246.
Hojahmat M., Horton D.B., Deaciuc A.G., Culver J.P., Crooks, P.A.,
Dwoskin L.P. Synthesis and evaluation of 3,5-disubstituted piperidine
analogs related to lobeline as vesicular monoamine transporter ligand.
American Association Pharmaceutical Scientists, Abstract, 2007.
Zheng G., Dwoskin L.P., Deaciuc A.G., Crooks P.A. Synthesis and
evalucation of quinuclidine-incorporated lobelane analogs as vesicular
monoamine transporter ligands. American Chemical Society Abstract
MEDI-267, 2007.
Horton D.B., Zheng G., Deaciuc A.G., Crooks P.A., Dwoskin L.P. Novel
vesicular monoamine transporter (VMAT2) inhibitors as potential treatments
for methamphetamine abuse: Interaction of meso-transdiene and lobelane
analogs at neurotransmitter transporters. Soc. Neurosci. Abstr, Abstract,
2007.
Joyce B.M., Zheng G., Ross J.T., Bardo M.T., Papke R.L., Crooks P.A.,
Dwoskin L.P. Discovery of novel nicotinic receptor antagonists for the
treatment of nicotine addiction: 1-trimethylammonium-10-[1-(3picolinium)]decane (TMPD) inhibits nicotine-evoked dopamine release from
rat striatal slices and decreases nicotine sel-administration. Soc. Neurosci.
Abstr, Abstract, 2007.
Narayanaswami V., Dhawan G., Cassis L.A., Dwoskin L.P. Diet-induced
obesity decreases dopamine transporter (DAT) function in the rat striatum.
Soc. Neurosci. Abstr, Abstract, 2007.
Nickell J.R., Deaciuc A.G., Zheng G., Crooks P.A., Dwoskin L.P.
Investigation of the selectivity of phenyl ring-substituted lobelane analogs for
VMAT2 in the development of novel therapies for methamphetamine abuse.
Soc. Neurosci. Abstr, Abstract, 2007.
Pivavarchyk M., Zhang Z., Crooks P.A., Dwoskin L.P. Tetrakis quaternary
ammonium salts: novel nicotinic receptor antagonists which inhibit nicotineevoked [3H]dopamine overflow from superfused rat striatal slices. Soc.
Neurosci. Abstr, Abstract, 2007.
Siripurapu K.B., Nickell J.R., Dwoskin L.P. Lobeline descreases
intravesicular dopamine content in rat striatum. Soc. Neurosci. Abstr,
Abstract, 2007.
Stokes C., Dwoskin L.P., Crooks P.A., Jacobs L.B., McIntosh J.M., Papke
R.L. The identification of selective competitive and noncompetitive nAChR
antagonists using alpha6 nicotinic acetylcholine receptor chimeras. Soc.
Neurosci. Abstr, Abstract, 2007.
Vartak A.P., Deaciuc A.G., Dwoskin L.P., Crooks, P.A. Design, synthesis
and pharmacological evaluation of novel analogs of the anti-addictive
alkaloid, lobeline. American Chemical Society, Abstract MEDI-454, 2007.
Williams Y.D., Dwoskin L.P. Effect of acute and chronic administration of
lobeline, methylphenidate, and emphetamine on straital dopamine
transporter function. Soc. Neurosci. Abstr, Abstract, 2007.
Zheng F., Zheng G., Deaciuc A.G., Zhan C.G., Dwoskin L.P., Crooks P.A.
Computational neural network analysis of the affinity of lobelane and
Linda P. Dwoskin
Curriculum Vitae
Page 62
247.
248.
249.
250.
251.
252.
253.
254.
255.
256.
tetrabenazine analogs for the vesicular monoamine transporter-2. American
Chemical Society Abstract MEDI-269, 2007.
Zheng F., Huang X., Dwoskin L.P., Crooks P.A., Zhan C.G. Prediction of
channel blocking effect of 5-n-alkyloctahydro indolizine analogs at the α4β2*
nAChR subtype. American Association Pharmaceutical Scientists, Abstract,
2007.
Zheng G., Dwoskin L.P., Deaciuc A.G., Crooks P.A. Synthesis and
evaluation of homologous analogs of lobelane at the vesicular monamine
transporter (VMAT2). American Association Pharmaceutical Scientists,
Abstract, 2007.
Zheng G., Dwoskin L.P., Deaciuc A.G., Crooks P.A. Synthesis and
evaluation of quinuclidine incorporated lobelane analogues as vesicular
monoamine transporter ligand. American Chemical Society, Abstract, 2007.
Zheng Z., Pivavarchyk M., Deaciuc A.G., Dwoskin L.P., Crooks P.A.
Tetrakis-quaternary ammonium salts: novel bPiDDB analogs as selective
neuronal nicotinic receptor antagonists for subtypes mediating nicotineevoked dopamine release. American Association Pharmaceutical
Scientists, Abstract, 2007.
Kehrberg A.H., Wellmann K.A., Lewis B., Estes A., Dwoskin L.P., Barron S.
Lobeline reduces hyperactitivy induced by neonatal alcohol exposure.
International Society for Developmental Psychobiology, Abstract, 2007.
Hojahmat M., Horton D.B., Deaciuc A.G., Culver J.P., Dwoskin L.P.,
Crooks P.A. Synthesis and evaluation of 3,5-disubstituted piperidino
analogs related to lobline as vesicular monamine transporter-2 ligands.
American Asociation Pharmaceutical Scientists, Abstract, 2007.
Wooters T.E., Ross, J.T., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T.
Effects of the novel nicotinic acetylcholine receptor antagonist, N,N’-decane1,10-diyl-bis-3-picolinium diiodide (bPiDI), on nicotine self-administration
and food-maintained responding in rats. College on Problems of Drug
Dependence, Abtract, 2007.
Crooks P.A., Zheng G., Pivavarchyk M., Dwoskin L.P. Inhibition of
nicotine-evoked dopamine release from superfused rat striatal slices by
novel quaternary ammonium salts containing an N-5-(3-biphenyl)pentyl-1-yl
substituent. College on Problems of Drug Dependence, Abtract, 2007.
Dwoskin L.P., Pivavarchyk M., Tsuneki, Toyooka N., Zhang Z., Crooks
P.A., Indolizidine 235B’ potently inhibits nicotine-evoked dopamine release
from superfused rat striatal slices. College on Problems of Drug
Dependence, Abstract, 2007.
Kantak K.M., Harvey R.C., Dembro K.A., Mutebi M. M., Singh T., Kerstetter
K. A., Dwoskin L.P., Deschepper C.F. Effects of oral methylphenidate on
prefrontal cortex-associated neurocognitive deficits in the spontaneous
hypertensive rat. Experimental Biology ‘08,
Linda P. Dwoskin
Curriculum Vitae
Page 63